Synthesis of (S)-cEt-LNA by Salinas Hernandez, Juan Carlos
  
i 
 
Université de Montréal 
 
 
Synthesis of (S)-cEt-LNA 
 
par 
Juan Carlos Salinas Hernandez 
 
 
Département de Chimie 
Faculté des Arts et des Sciences 
 
 
 
Mémoire présenté à la Faculté des Études Supérieures et postdoctorales 
en vue de l’obtention du grade de Maître ès Sciences (M.Sc.) 
en Chimie 
 
 
April 2014 
 
 
© Juan Salinas Hernandez, 2014 
ii 
 
To my family 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Résumé 
Nucleoside (S)-cEt-LNA a été synthétisé par trois voies différentes à partir de la 5-
méthyluridine qui est commercialement disponible. Le chemin le plus court comprend une 
méthylation diastéréosélective d'un aldéhyde, et une cyclisation 5-exo-tet d'un éther par 
déplacement SN2. 
Mots-clés: (S)-cEt-LNA, technologie antisens, nucleoside. 
 
 
Abstract 
(S)-cEt-LNA nucleoside was synthesized by three different routes starting from 
commercially available 5-methyluridine. The shortest route includes a diastereoselective 
methylation of an aldehyde, and a 5-exo-tet cylization of an ether via SN2 displacement. 
Keywords: antisense technology, (S)-cEt-LNA, nucleoside. 
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1 Chapter One – Introduction  
1.1 DNA and RNA structure 
The nucleotides are the monomers of the polymeric macromolecules called nucleic acids. Each 
nucleotide is composed of three parts: the sugar backbone, the nitrogenous base and a phosphate 
residue. The sugar present in the nucleic acids is a pentose, which depending on the substitution 
at the position 2', can be D-ribose (-CH-OH) or D-deoxyribose (-CH2-) (Figure 1a). In DNA the 
deoxyribose is the constituent sugar of the nucleic acid, while in RNA, ribose is the sugar present 
in the nucleic acid. 
In both DNA and RNA, the pentose is substituted by a phosphate group as a linker to form a 
chain that constitutes the backbone of the nucleic acid. The phosphate bond is formed between 
the 3'-OH of one pentose to the 5'-OH of another pentose, thus forming a phosphodiester bond. 
In the anomeric position of each sugar (1'), there is a nitrogenated heterocycle called 
“nucleobase”, which is cis (β face) to the hydroxymethyl group at the 5' position. The 
nucleobases are classified as purines and pyrimidines. Purines consist of a five-membered and 
a six-membered nitrogen-containing ring, fused together; part of this family are adenine and 
guanidine. On the other hand pyrimidines, such as cytosine, thymine and uracil, have a six-
membered nitrogen ring. Adenine, guanidine and cytosine are found in both DNA and RNA. 
Uracil is found exclusively in RNA. 5-Methyl uracil, thymidine, is present only in DNA. 
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Figure 1. a) Generic nucleic acid double strand. b) Minor and major groove of helix formed 
by double strand nucleic acids. 
Thanks to the X-ray diffraction pattern analysis data taken in the 50’s1 and to chemical analysis, 
it was demonstrated that the amount of adenine (A) is always the same as the amount of thymine 
(T). Similarly, the amount of guanine (G) is always equal to the amount of cytosine (C). It was 
concluded that DNA was a double strand, where the nucleobases of each chain forms hydrogen 
bonds with its other chain counterparts. Further studies on the helical structure of DNA 
concluded that exclusively the pairs cytosine-guanine and adenine-thymine were always present 
along the double strand. This complementary behavior dictates that each strand of the DNA is 
exactly like the other one but linked in an opposite direction.1a  
The interactions between the different nucleobases are unique. The pair guanine-adenine forms 
three hydrogen bonds, while the pair cytosine-thymine only shows two hydrogen bonds. As 
result, DNA with higher percentage of G-A becomes more stable.  As the hydrogen bond is a 
non-covalent bond, it is possible to separate the double strand. This process is reversible in 
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solution; however, it is necessary to heat the DNA. The temperature at which fifty percent of 
the molecules of DNA are separated in 2 single strands, is called “the melting temperature 
(Tm)”. This value is an indicator for measuring the stability of DNA and its derivates. Several 
techniques have been developed for the measurement of the Tm. One of the most common is 
based on measuring the absorption of UV light by the nucleobases present in DNA, which 
exhibit a maximal absorption at 260 nm. Complementary pairs of nucleobases interact with each 
other pair of nucleobases by stacking of their pi-cloud electrons and by formation of hydrogen 
bonds. When the DNA is unwound to form two single strands, the stacking is weakened thus 
increasing the absorption of light in a phenomena called hyperchomicity.  
The duplex formed by two strands of DNA or two strands of RNA assumes a right-handed helix 
where the nucleobases are stacked in the inner part of the helix and the sugar-phosphate polymer 
is installed in the exterior of the helix. The RNA and DNA duplex present a difference in the 
size and shape of the grooves formed by the helix (Figure 1b). The DNA forms a type B helix 
where the major groove is wider than the minor groove. The RNA duplex shows a more compact 
and stable helical structure, with a major groove smaller than in DNA duplex.  
 
1.2 DNA transcription 
Transcription is the process of copying the genetic information found in the double-stranded 
DNA into a single stranded RNA, which is complementary to the segment of DNA from which 
it was copied. In order to begin the transcription process, it is necessary to have the four 5'-
triphosphate nucleosides (C, U, G, A), magnesium (II) and RNA polymerase (RNAp). RNAp is 
an enzymatic complex formed by several enzyme subunits. RNAp recognizes specific 
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sequences in DNA (promoters) to start the transcription process. When the RNAp binds to the 
double-stranded DNA, it is necessary to unwrap a sequence consisting of about 14 base pairs. 
The gap formed will move through the DNA, opening and closing the double strand on its way. 
The RNA synthesis starts inside this transcription bubble where each new nucleoside that joins 
the chain, is chosen following the complementary base on DNA. The process of RNA synthesis 
continues until the DNA encodes a sequence (transcriptor terminator) that forms a loop in the 
RNA that helps to dissociate the RNAp transcription complex, and releases the new RNA strand 
(primary transcript).  
 
1.3 RNA processing 
In eukaryotic cells, the RNA obtained from the transcription (primary transcript) stills needs to 
undergo some changes in its structure in order to be able to transmit the stored genetic 
information. The first transformation of the primary transcript is addressed by imparting stability 
of the newly synthesized RNA strand towards nucleases, which are enzymes that cleave the 
phosphodiester bond. This is achieved by capping at the 5' position with 7-methylguanosine 
linked through a 5'-5' triphosphate bond (Figure 2).2 Other modifications include the 
methylation of the 2'-OH of the first and second ribose units in the strand, and the addition of a 
long tail (between 100 and 200) of adenine ribonucleotides known as poly(A) at the 3' end of 
RNA.3  
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Figure 2. RNA processing 
The next step is the splicing of the stabilized RNA (Figure 2) where some sequences, known as 
introns, are deleted. The amount of sequences removed as introns depends on each specie, but 
at the end all the remaining parts that codify for a gene (exons) are joined, forming the final 
mRNA responsible of translate the genetic message.  
 
1.4 Protein synthesis – Translation 
The synthesis of proteins (translation) is carried out in the rough endoplasmic reticulum (RER) 
and performed within the ribosome, which is a large macromolecular complex made by both 
RNA and proteins. The amino acids that will form part of the protein are carried to the ribosome 
by transfer RNA (tRNA), a kind of RNA that is bonded to an amino acid and is able to recognize 
sequences of mRNA. The way to interpret the information is by reading the sequences of 
nucleosides in groups of three (triads), which are called codons. Each codon is responsible of 
codifying for a specific amino acid, although one amino acid can be codified by different 
codons.  
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The translation process begins when the first molecule of tRNA interacts with the mRNA 
detecting the initiation codon and binding in presence of the ribosome (Figure 3). With the 
ribosome reading the information and moving through the mRNA from the 5' to the 3' end, a 
second molecule of tRNA recognizes the next codon and brings the corresponding amino acid 
to the complex. The two amino acids react by forming a peptide bond, while the ribosome moves 
to the next codon, adding more amino acids and releasing the now empty tRNA. The rate of 
protein synthesis in eukaryotes can reach up to 14 to 18 amino acids/second per ribosome4. The 
process continues until a codon is reached which does not codify for an amino acid (stop codon). 
That last codon is recognized by a protein called “releasing factor”, which helps the protein 
synthetized to be expelled from the complex finishing the translation process. 
 
 
Figure 3. Translation process 
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2 Chapter Two – Antisense technology 
 
2.1 History 
In 1978 Stephenson and Zamecnik5 working with chick embryo fibroblast cells infected with 
Rous sarcoma virus (RVS), achieved the inhibition of the production of the virus with a 
synthesized oligodeoxynucleotide. In the primary structure of the RVS there are identical 
sequences of nucleosides next to the 5' cap and poly(A) 3' end. The 21-nucleoside sequence was 
the target of the study applying a synthetically prepared ribonucleoside, complementary to a 
segment of the target sequence. The 13 nucleotide sequence d(AATGGTAAAATGG) was 
bonded to the target sequence, blocking the normal functioning of the virus by competitive 
hybridization.  
Together with many subsequent studies, it was realized that using the RNA as a target, it would 
be possible to treat different diseases related to the malfunction of RNA, or to block the 
translation process in the cell. The complementary nucleotide chain is called “antisense” 
because it has a sequence of bases complementary to the sense of the message in RNA (5' to 3').  
Binding to the target RNA is the general mechanism of action of all the antisense 
oligonucleotides (ASO).  
2.2 Molecular mechanism of action 
The multiple types of RNAs and their multiple roles in the cell have become a growing area of 
interest with therapeutic potential in recent years. This includes the historically important 
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mRNA, the small nuclear RNA (smRNA) that plays key roles in the splicing process and the 
less studied microRNA which seems to act as a natural gene regulator. Thus, the RNA molecule 
in general is a very attractive target in the development of new kinds of therapies for the 
treatment of diverse diseases. 
 
2.2.1 RNA cleavage 
The destruction of the RNA chain by a family of enzymes called RNase H is the most direct 
approach to inactivate its biological function. These enzymes found in mammals recognize the 
RNA-DNA duplex and hydrolyze the phosphodiester bond in the RNA and release the intact 
DNA strain.  
 
Figure 4. RNase H active site6.The active site RNase in complex with the RNA/DNA hybrid. 
Active-site residues are shown in green; the RNA strand in pink, orange, and red; and the 
magnesium ions as yellow spheres. The water molecule positioned to attack the scissile 
phosphate is indicated. Metal-ion coordination is shown as dashed yellow lines. 
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This happens when the enzyme recognizes7 both, the RNA and the DNA strands. The duplex 
fits in two grooves in the enzyme structure with the 2’-OH of five consecutive nucleotides of 
the RNA strand interacting with one groove in the active site of the enzyme.6 Different active–
site residues of the enzyme like carboxylate and amino groups form hydrogen bonds with the 3’ 
and 5’ sides of the phosphate bond to be cleaved (Figure 4). In the active site is also found two 
Mg2+ ions, chelated by four carboxylate groups and two molecules of water. One of the 
molecules of water attacks the phosphate linkage, assisted by one oxygen of the phosphate group 
that orients the attack and serves as a general base for deprotonation. After the attack, the other 
metallic ion stabilizes the 3’-OH group from the cleaved phosphodiester bond. The use of a 
designed ASO, that binds a RNA target in order to destroy and therefore supress the function 
on the cell, has been the subject of hundreds of studies.8 Depending on the structure of the 
nucleotides that form the ASO, the duplex ASO-RNA can support the RNase H activity resulting 
in the hydrolysis of the RNA target. Surprisingly, some modifications focussing on increasing 
the metabolic stability and increasing the affinity towards the target RNA, resulted in a loss of 
RNase H activity9, thus forcing the use of ASO hybrids composed by sections that support the 
RNase activity and others sections that provide the affinity to the complementary RNA. 
 
2.2.2 Non RNA cleavage 
Antisense oligonucleosides (ASOs) can be designed to work as competitive antagonists, binding 
to specific sequences in RNA and interrupting the normal interactions with proteins, enzymes, 
or other factors in the cell. One of the processes that can be affected is the maturation of RNA 
primary transcript, a fundamental step to obtain different functional RNAs such as mRNA and 
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tRNA. Inhibition of 5’ capping on RNA may be performed by designing an ASO capable of 
binding to the 3’ end of the primary transcript. However, to date there is no report of this 
approach in antisense technology. Another fundamental step in RNA processing is the splicing. 
Therefore, if an ASO is bound to a sequence in RNA that had to be spliced, a barrier will be 
imposed and the splicing suppressed. Promising approaches focussed on interrupting or 
modifying the RNA splicing process have been reported, for example, the use of ASOs by Kole, 
proved to be efficient in the correction of an aberrant splicing in mutated RNA, restoring the 
correct splicing site.10 ASOs designed to bind with high affinity to the 3’-splice sites in murine 
pre mRNA exhibit good activity in deletion of specific exons, resulting in the inhibition of 
mRNA production and suppression of protein synthesis.11  
 
2.3 ASO modification 
Obtaining a higher resistance against the degradative action of nucleases was the first challenge 
in the ASO design. Replacing a non-bridging oxygen in the phosphodiester linkage by a sulfur 
atom gave as result a high resistance of the new modified nucleotides12 toward action of 
hydrolases. This new type of nucleosides received the name of phosphothioate (PS) nucleosides 
(Figure 5a). When the RNA-PS nucleotide duplex is formed, attack of the RNase occurs, which 
hydrolyzes the RNA strand and releases the PS nucleotide, blocking the production of the 
protein. The first use of an PS oligonucleotide was reported by Matsukura,13 where 
oligonucleotides containing the phosphotioate modification showed inhibition in vitro against 
human immunodeficiency virus (HIV). Although PS oligonucleotides present a slightly similar 
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affinity for the RNA compared to natural nucleic acids,14 they exhibit tendency towards non-
specific interaction with certain proteins15 causing undesired effects in the body. 
 
Figure 5. a) Generations of ASOs. b) North and South type conformation. c) Example of Gap 
design oligonucleotide with MOE. 
 
The next generation of ASOs was designed to increase both the affinity with the RNA, and the 
nuclease resistance. Between all kinds of reported modifications, two types of ASOs have been 
widely studied. Methylation of the 2’-OH of pentose gives rise to the 2’-O-methyl nucleoside 
(Figure 5a). This modification blocks the possibility of self-hydrolysis of the phosphodiester 
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linkage by attack of the 2’-OH. The 2’-O-methoxyethyl (MOE) nucleosides together with the 
PS backbone modification established the most studied second generation of ASOs.16 The 
methoxyethyl group assumes a rigid conformation due to the gauche effect between the two 
oxygen atoms. The MOE group also forms hydrogen bonds with a molecule of water that acts 
as a protecting shield of the phosphodiester bond which results in an increased resistance against 
nucleases.17  
Together with the 2’-fluoro modification (Figure 5a), the 2’-O-alkyl modification confers to the 
nucleoside a north type conformation (Figure 5b) that shortens the distance between the 3’-5’ 
phosphate bonds, generating, a more compact structure that assumes a type A helix 
conformation, increasing the affinity of the ASO to the RNA.  
The second generation modifications resulted in a decrease in the toxicity associated with the 
first generation of ASOs,18 but also presented some difficulties in the design of new 
oligonucleotides, being incompatible with the action of the RNase and the RNA cleavage 
mechanism. This limitation was overcome by the use of a “gap” design9 (Figure 5c), which uses 
2’-O-alkyl nucleosides in the 3’ and 5’ end of the chain, and a central DNA region of PS 
nucleosides.  In the gap design, the modified nucleosides located at the ends of the ASO increase 
the affinity for the RNA, and the PS internal chain supports the action of the RNase H for the 
cleavage of the target RNA. The success of the second generation of ASOs was shown by the 
approval in January 2013 of the gap designed oligonucleotide KYNAMRO™ by the FDA, a 
medicine for the treatment of homozygous familial hypercholesterolemia.19 
The third generation of ASOs contain different modifications on the carbon backbone. One of 
the more drastic changes was found in the peptide nucleic acid (PNA) (Figure 5a). Designed 
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with a pseudopeptide backbone, consisting of N-(2-aminoethyl)-glycine, this PNA shows great 
affinity to RNA and DNA. Due to its pseudopeptidic structure, PNA is resistant to degradation 
of nucleases and proteases, but they are not compatible with the RNase mechanism of action. 
This stability makes the PNA a good candidate for its use in the disruption of RNA processing, 
by the translation inhibition20 and splicing modulation mechanisms.21   
Locked nucleic acid (LNA)22 is a restricted analog  of 2’-OMe nucleoside, where the 2’ hydroxyl 
group methyl is tethered to the 4’-carbon (Figure 5a). The resulting bicyclic structure confers to 
the molecule a north type conformation that presents an improved stacking between the 
nucleobases compared to the RNA duplex.23 Studies modifying the position of LNA in gap 
designed oligonucleotides, concluded that a gap of at least 8-DNA nucleosides is necessary to 
induce efficient RNase cleavage.24 Further studies have shown the successful use of a LNA-gap 
design.25  
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3 Chapter Three – Synthesis of (S)-cEt-LNA 
 
3.1 Original synthesis of (S)-cEt-LNA 
 
In 2010 Seth et al. reported the synthesis of a new generation of modified nucleosides.26 The 
2’,4’-constrained MOE (cMOE) (Figure 6) was designed to combine the reduced toxicity of 
MOE nucleotides, with the great affinity showed by LNA nucleosides. To achieve the desired 
properties, the methoxyethyl group found in MOE was restricted covalently to the 4’ position 
forming a bicyclic structure as in LNA. Both (R) and (S)-cMOE isomers, showed high resistance 
against nuclease attack but when tested in vivo, cMOE ASOs exhibited a considerably 
diminution in activity compared to LNA ASOs.27 The reduced activity was attributed to the 
steric hindrance generated by the terminal O-methyl group, so it was hypothesized that the 
removal of the methoxy end, will restore the biological activity.  
 
Figure 6.  cMOE and cEt-LNA nucleosides 
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Given the previous results, both isomers of the 2’,4’-constrained ethyl LNA (cEt-LNA) (Figure 
6) were synthetized an tested. The cEt-LNA can be seen as a 6’-methylated analog of LNA, or 
a cMOE without the methoxy chain at 6’ position.  When introduced in ASOs, they presented 
no hepatotoxicity in mice expressed as a measure of the transaminases level. The thermal and 
nuclease stability of ASOs containing (S)-cEt-LNA were also studied. The results showed that 
oligonucleotides containing (S)-cEt-LNA present higher stability than those containing LNA.28 
Exposure of a 10-mer poly T DNA oligomer with two (S)-cEt-LNA modifications at the 3’ end 
to snake venom phosphodiesterase, revealed that the LNA oligomer was completely hydrolyzed 
in 1290 min while the (S)-cEt-LNA modified chains were >70% intact. 
The original synthesis of (S)-cEt-LNA started from the commercially available diacetone D-
allofuranose (Scheme 1). Protection of the free alcohol with 2-naphthyl bromide provided 1 in 
quantitative yield. Hydrolysis of the exo-acetal in 1, cleavage of the diol to furnish the aldehyde, 
and aldol reaction with formaldehyde afforded 2 in 66% yield over 3 steps. Selective protection 
of the diol moiety in 2, gave 3 in addition to bis silylated products. Oxidation of the primary 
alcohol under the Swern conditions, and treatment of the resulting aldehyde with MeMgBr, 
produced 4 in a ratio of 10:1 of the desired (S)-alcohol. A sequential oxidation/reduction led to 
5 as a single isomer. Mesylation of the secondary alcohol in 5 followed by acetolysis furnished 
6 in 90% yield over two steps.  Vorbrüggen reaction of the diacetate 6 installed the 5-
methyluridine moiety at the anomeric position of the sugar. Cleavage of the 2’-OAc, and 
intramolecular displacement of the mesylate group gave bicyclic nucleoside 7. Finally, cleavage 
of the 3’-ONap protecting group gave the 5’-TBDPSO-(S)-cEt-LNA in 14 steps and 22% overall 
yield. 
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Scheme 1. Original synthesis of (S)-cEt-LNA. 
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3.2 Retrosynthetic analysis of (S)-cEt-LNA 
It was envisaged that the 2',6'-ether bridge in (S)-cEt-LNA can be formed via SN2 displacement 
of an appropriate leaving group by the 2' alcohol of the nucleoside A (Scheme 2). This approach 
has been successfully applied in the synthesis of complex nucleosides bearing the protected 3’-
OH.29 In our case, we face a 4-exo-tet vs. 5-exo-tet cyclization both favored by Baldwin rules,30 
but the formation of the 4-member ring was expected to be less favored due to the ring strain 
generated in the oxetane product.  With this strategy in mind, the selective addition of a methyl 
group to the corresponding aldehyde to obtaining the (R)-alcohol B, required particular 
attention. The desired configuration would be achieved during the inversion in the SN2 
displacement. 
 
Scheme 2. Retrosynthetic analysis of (S)-cEt-LNA 
 
The free alcohol on the α-face of the nucleoside can be obtained via protection-deprotection 
sequence on C. The compound C can be easily obtained from 5-methyluridine.  
18 
 
As the main objective of the project was to develop a synthetic route that provides (S)-cEt-LNA 
in large scale with a reduced number of synthetic steps, and an improved overall yield compared 
to the original route, we decided to use 5-methyluridine ($4.33 per mmol) as starting material 
vs. diacetone D-allofuranose ($16.8 per mmol). Furthermore this approach avoids the 
introduction of the 5-methyluracil moiety late in the synthesis.  
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3.3 First Generation Synthesis 
The first objective towards (S)-cEt-LNA consisted in obtaining the key intermediate 5 (Scheme 
3), which takes advantage of the inherent functionality of the molecule in order to avoid the use 
of multiple protecting groups. The formation of a 2-5' anhydronucleoside as a key intermediate 
gives a dual protection to the 5' OH and the 3-NH of the nucleobase. 
 
 
Scheme 3. Retrosynthetic analysis of anhydronucleoside key intermediate 5. 
 
Starting from 5-methyluridine, protection of the cis-2',3' diol as a cyclohexylidene acetal 
provided 1 in 96% yield (Scheme 4). Oxidation of the primary alcohol using Dess-Martin 
periodinane31 followed by cross-aldol reaction with formaldehyde and one-pot reduction 
following the Moffatt protocol32 gave diol 2 in 51% yield. Treatment of the diol with triflic 
anhydride in pyridine afforded bistriflate nucleoside that was subsequently treated with DBU, 
resulting in the displacement of the 5'-OTf, to give anhydronucleoside triflate 3. Different 
conditions were used such as H2O/THF, LiOH/H2O2, TBAOH, NaOH/THF, focused on 
displacing the remaining triflate in order to obtain the alcohol, the acetate or directly the 
aldehyde via a Korblum oxidation.33 They proved to be unsuccessful leading to the opening of 
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the anhydro bridge. A known reaction in carbohydrate chemistry consists in the displacement 
of triflates by nitrite salts forming an alcohol with an inverted configuration.34 In our system, 
the use of NaNO2 in DMF provided the corresponding alcohol 4 in low yield. However, when 
the nitrite source was replaced by TBANO2 in THF, alcohol 4 was obtained in 85% yield.  
Oxidation with DMP gave aldehyde 5 in 85 % yield. 
 
 
Scheme 4. Synthesis of key intermediate 5. 
An alternative route to the key intermediate 5 was performed through the treatment of 2 with 
TBDPSCl affording the protected of the β-5’-alcohol in 68% yield. The regioselective protection 
of the α-5’-hydroxymethyl vs. the β-5’-hydroxymethyl could also be achieved by using bulky 
such as Tosyl, TBS, TBDPS and Tr. 
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With 6 in hands, we proceeded to install a triflate on the remaining 5’-hydroxymethyl group, 
followed by a DBU mediated displacement to yield 7. Silyl ether cleavage by TBAF and DMP 
oxidation afforded the key intermediate 5. Interestingly, when the mesyl group is used instead 
of the triflate as leaving group in 6, the displacement to produce 7 did not work.  
With compound 5 in hand, we tried adding different methyl sources like MeMgBr, MeLi, 
Me2CuLi and AlMe3, but they all gave low yields and poor diastereoselectivity.  Additionally, 
the opening of the anhydro bridge led to by-products, showing signs of its labile character. 
Analyzing the conformation of the molecule it was suspected that due to the anhydro bridge the 
molecule will be in a non-favorable conformation for the desired attack from the 2'-OH in a 5-
exo-tet cyclization, leading us to abandon this route. 
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3.4 Second Generation Synthesis  
The second approach consisted of a protection-deprotection sequence to differentiate between 
the α and β-5’-hydroxymethyl groups in 2 (Scheme 5). This is based on the higher reactivity of 
the hydroxymethyl on the α-face of the sugar due to favorable steric reasons. The first attempt 
to protect the α-hydroxymethyl alcohol was using standard benzylation conditions (BnBr, NaH), 
but the basic conditions produced mixtures of the desired product and a side-products derived 
from the benzylation at N-3 of the nucleobase. A better selection of the protecting group led to 
the use of trityl chloride to obtain 8 in 70% yield. Introduction of TBDPS group for the 
protection of the remaining alcohol gave compound 9.  Cleavage of the trityl group under acidic 
conditions, was followed by oxidation with Dess-Martin periodinane (DMP) to the 
corresponding aldehyde. Diasteroselective methylation with AlMe3 in toluene gave 11 in 68% 
yield as a single isomer. The relative configuration of compound 11 could not be fully 
established at that point. However, by comparison with known C5’-OPiv analog it was thought 
to be the (S)-alcohol. In order to invert the configuration of the alcohol we used an oxidation-
reduction sequence of the ketone, starting with the use of DMP on nucleoside 11, then reduction 
of the crude mixture with LiAlH4 at -78 °C to afford 12 as a single isomer. 
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Scheme 5.  Synthesis of intermediate alcohol 12. 
The observed selectivity in the methylation to obtain 11 can be explained using the Cram chelate 
model, where the addition of AlMe3 takes place through a chelated state between the oxygen of 
the aldehyde and the oxygen of the furanose ring (Figure 7). Due to the steric hindrance created 
by the 5'-OTBDPS it would be expected that the methyl group would be delivered on the si face 
of the aldehyde, via a AlMe3-dimer.
35 In the case of the oxidation-reduction sequence with 
LiAlH4 to form 12, the same steric assistance and chelate formation would provide the selective 
transfer of the hydride on the si face of the methyl ketone. 
 
Figure 7. Proposed Cram chelate model for the diastereoselective methyl and hydride 
additions. 
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The next alternative was to invert the 6’-OH group via the mesylate 13 (Scheme 6). Cleavage 
of the cyclohexylidene acetal under acidic conditions gave the diol 13 in 52% yield over two 
steps (Scheme 6). At this point, the first attempt to directly cyclize diol 13 to obtain the (S)-cEt-
LNA, led to the four membered oxetane ring 14 from the 4-exo-tet cyclization mode in 90% 
yield. The structure of 14 was correlated with the 5'-OH pivaloyl analog provided by Isis 
Pharmaceuticals.  With the aim to complete the synthesis, it was decided to use a detour by 
protecting the diol moiety in 13 as a benzylidene acetal. Selective reductive cleavage36 of the 
diastereomeric mixture of acetals in 15 was achieved by treatment with TiCl4/NaBH3CN to 
furnish the 2'-OH free nucleoside, which then, readily cyclized under basic conditions to give 
16. Different attempts to cleave of the benzyl ether on 16 via hydrogenolysis were unsuccessful 
(Pd(OH)2, Pd/C). When harsher conditions were employed (Pd(OH)2, ammonium formate), the 
nucleobase underwent double bond reduction as reported previously.37  
 
Scheme 6. Synthesis of 3'-benzyl-(S)-cEt-LNA 16 and oxetane 14. 
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3.5 Third Generation Synthesis 
Due to the challenges presented with the removal of the benzyl group in 16, it was decided to 
use a similar strategy by protecting the 2',3' diol with a more labile protecting group. The chosen 
group was the naphthylidene acetal, which in principle should show the same regioselectivity 
during the reductive cleavage just as the benzylidene acetal did. First, protection of the vicinal 
diol in 5-methyluridine with commercially available 2-naphthaldehyde, resulted in low yield 
and poor conversion. Therefore, it was decided to use the more reactive naphthaldehyde 
dimethyl acetal. The naphthylidene dimethyl acetal is not commercially available, so it was 
prepared starting from 2-naphthaldehyde38 and used without further purification. The reaction 
of 5-methyluridine with naphthaldehyde dimethyl acetal catalyzed by CSA proceeded smoothly 
in 85% yield furnishing a mixture of diasteroisomers at the acetal carbon atom of 17 (Scheme 
7). Unfortunately, the sequence of oxidation/aldol reaction/ reduction to produce 18 was not 
only low yielding but also had solubility issues. 
 
 
Scheme 7. Synthesis of diol 18. 
 
Reductive cleavage of the acetal at the 2' position in 17 gave 19 in 94% yield (Scheme 8). Double 
protection of the primary and secondary alcohols in 19 with TBSCl and subsequent cleavage of 
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the silyl group on 5'-OH gave nucleoside 20. The use of the same sequence for the synthesis of 
2, was employed on 20 furnishing the 6’-hydroxymethyl analog 21 in 48% yield over two steps. 
This time, the use of trityl chloride proved to be effective to get compound 22, which then 
followed the same sequence of protecting groups used during the first approach, affording 
compound 24 in 54% over three steps. Transformation of compound 22 into 24 can be done in 
a one pot procedure in 69% yield.  
 
 
Scheme 8. Synthesis of intermediate 24. 
 
The aldehyde obtained from oxidation of 24 was treated with AlMe3 to give the secondary 
alcohol 25 which was readily mesylated to obtain nucleoside 26 (Scheme 9). Deprotection of 
the 2'-OH and cyclization under basic conditions furnished compound 27, whose 1H NMR did 
not correspond to the desired product. From this result it was clear that the addition of the methyl 
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group on 25 gave the undesired (S)-isomer at 6’-position. Therefore, it was necessary to oxidize 
to the corresponding ketone with DMP and reduce with LiAlH4 to obtain the (R)-isomer. In the 
study of the fourth generation synthesis, we found that the use of cuprates instead of AlMe3 
provided the (R)-alcohol as major product. Applying these conditions to the aldehyde obtained 
from oxidation of 24, led to formation of alcohol 28 in 44% yield over two steps. With 
compound 28 in hand, mesylate 29 was prepared, then displaced by the 2’-alcohol after cleavage 
of the 2'-OTBS in 29 and treated with K2CO3 in MeOH. The  
1H and 13C NMR for compound 
30 matched with the one reported by Isis Pharmaceuticals.37  
 
Scheme 9. Synthesis of 3'-naphthyl-(S)-cEt-LNA 30. 
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3.6 Fourth Generation Synthesis 
The last generation synthesis was focussed on optimizing and reducing the number of total steps, 
in addition to improving the selectivity in the key steps of the synthesis using the knowledge 
obtained from the previous syntheses. During the first generation approach, the protection of the 
diol in 5-methyluridine was accomplished by the use of cyclohexanone as solvent which forced 
us to purify the product by flash chromatography in order to remove large excess of unreacted 
ketone. In order to improve the efficiency of this process, it was changed to cyclohexanone 
dimethyl acetal in 1,2-dichloroethane. This reaction furnished protected 5-methyluridine with a 
purity up to 95%, allowing its use in the subsequent step without further purification. Oxidation 
of the crude alcohol with DMP, followed by aldol condensation with formaldehyde and 
reduction with sodium borohydride afforded 2 in 62% yield (Scheme 10).  
 
Scheme 10. Synthesis of compound 32. 
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Transformation of 2 into 10 was previously accomplished in three steps with a purification 
between each step (Scheme 5). In the current approach, the number of purifications was reduced 
without significantly sacrificing the yield, adopting a one-pot procedure to protect the α-5’-
hydroxymethyl group with TBSCl at 0 °C followed by adding an excess of TBDPSCl.  The 
reaction mixture containing the TBS/TBDPS-nucleoside and other silylated products was then 
diluted with methanol and treated with TFA to cleave the more acid sensitive TBS group, thus 
giving 10 as product after purification by flash chromatography. All the remaining fractions 
containing other silylated products were concentrated, dissolved in anhydrous THF, and treated 
with TBAF recovering 2 as product that was eventually recycled.  
In the search to obtain alcohol 12 without the oxidation/reduction sequence, it was found that 
the system MeLi/CuI in Et2O affords the desired (R)-alcohol as a major product. The change of 
solvent (Scheme 10) from Et2O to the safer MTBE, led surprisingly to increased selectivity, 
giving (R)-alcohol in a ratio up to 8:1 in 51% yield over 2 steps. Standard conditions for O-
tosylation of 12, provided nucleoside 31 which was then treated with a mixture of 
HCl/MeOH/THF to remove the cyclohexylidene acetal affording diol 32 in good yield. 
With diol 32 in hand, several conditions to favor the formation of the 5-membered ring 
tetrahydrofuran over the 4-membered ring oxetane were studied (Table I). In entry 2-6, the use 
of pyridine showed a selectivity towards the five-membered ring, albeit requiring long reaction 
times or a sealed tube to complete the reaction. The use of magnesium bromide or water as co-
solvent decreased the selectivity of the reaction. Driven by the promising results obtained with 
pyridine, different compounds bearing the pyridine scaffold such as 2,2’-bipyridine, quinoline, 
phenanthridine, and 1,10-phenanthroline were screened (entry 7-11), obtaining the best ratio 
with the latter (entry 11). 
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Employing common amine bases such as DBU, NEt3, DIPEA, imidazole or TMP (entry 12-18) 
gave low selectivity towards the 5-exo-tet cyclization product 33. Bicyclic guanidines (entry 19-
23), that in principle present dual activation through hydrogen bonding39, were also tested 
providing the oxetane 14 as product. The five and six-member ring cyclic amidines in entry 24 
and 25 were not effective in performing the desired selective cyclization producing a complex 
mixture in the case of entry 24. Similarly, bases such BEMP and N-methylmorpholine produced 
14 as major product (entry 26 and 27).  Other less conventional conditions including salts, basic 
alumina, molecular sieves, and silica gel did not give satisfactory results with exception of the 
last, where a reasonable ratio of the desired compound was obtained albeit with low conversion.  
Table I. Screening conditions for 5-exo-tet-cylization  
 
Entry Condition Ratio 14 : 33 : SMa 
1 Potassium carbonate, MeCN 10 : 1 : 0 
2 Pyridine, 80 °C, 3 days. 1 : 1.7 : 0 
3 Pyridine, MgBr2 (2 equiv.), 80 °C, 3.7 : 1 : 0 
4 Pyridine anhydrous, 80 °C, 24 h 
1 : 1.8 : 12.5* 
1 : 2.1 : 10* 
5 Pyridine/H2O 10:1, 80 °C, 20 h 1 : 1 : 1.2 
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6 Pyridine anhydrous, sealed tube, 120 °C, 20 h 1 : 1.6 : 0 
7 2,6-lutidine (3 equiv.), toluene reflux, 24 h 2 : 1 : 0 
8 
(2 equiv.), toluene, 80 °C, 20 h 
1 : 1 : 22 
9 
Base (  (2 equiv.), toluene, 80 °C, 20 h2h 1 : 0.9 : 5.6  
10 
 (2 equiv.), toluene, 80 °C, 20 h 
 
1 : 1.5 : 5.1 
11 
 (2 equiv.), toluene, 80 °C, 20 h 
1 : 2 : 2.6 
12 DBU, dioxane 3.8 : 1 : 0 
13 
 
DBU (2 equiv.), toluene, 80 °C, 24 h 
3.5 : 1 : 5 
14 Triethylamine (2 equiv.), DMSO, 80 °C, 24 h 1.3 : 1 : 0.3 
15 DIPEA (5 equiv.), toluene, 80 °C, 48 h 5 : 1 : 1 
16 Imidazole (2 equiv.), toluene, 80 °C, 24 h 1 : 1 : 0 
17 1-methylimidazole (2 equiv.), toluene, 80 °C, 24 h 3 : 1 : 10 
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18  (2 equiv.), toluene reflux, 48 h 
2 : 1 : 0 
 
19  (2 equiv.), toluene, 80 °C, 24 h 
5 : 1 : 0 
 
20  (2 equiv.), toluene, 80 °C, 24 h 
6.6 : 1 : 0 
 
21  (2 equiv.), toluene, 80 °C, 24 h 
6.6 : 1 : 0 
 
22  (2 equiv.), toluene, 80 °C, 24 h 
 
1.2 : 1 : 1.3 
 
23  (2 equiv.), toluene, 80 °C, 24 h 
 
2.3 : 1 : 12.5 
 
24 
 (1.5 equiv.), toluene, 80 °C, 24 h 
 
Decomposition 
 
25 
 (1.5 equiv.), toluene, 80 °C, 24 h 
 
1 : 1 : 8.5 
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, Toluene, rt, 36 h 
>20 : 1 : 0 
27 
 (2 equiv.), toluene, 80 °C, 20 h 
7 : 1 : 0 
28 MgBr2 (2 equiv.), toluene, 80 °C, 20 h 6 : 1 : 0.8 
29 LiBr (2 equiv.), toluene, 80 °C, 20 h 6.2 : 1 : 1.6 
30 TBAOAc (2 equiv.), toluene, 80 °C, 20 h 3.4 : 1 : 0 
31 Molecular sieves, toluene, 80 °C, 24 h 8.5 : 1 : 14* 
32 Basic alumina, toluene, 80 °C, 20 h 1 : 1 : 4 
33 Silica gel, toluene, 80 °C, 20 h 1 : 2.5 : 30* 
34 DMF, 80 °C, 24 h 1.8 : 1 : 7.4* 
35 , toluene, 80 °C, 24 h No Rxn 
36 
, 80 °C, 24 h 
1 : 2.1 :11* 
37 DMSO, 80 °C, 24 h 
1 : 2.7 : 1 
1 : 2.6 : 5.7 (duplicate) 
 
38  (2 equiv.), toluene, 80 °C, 20 h 
 
No Rxn 
34 
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 (2 equiv.), toluene, 80 °C, 20 h 
No Rxn 
40 
 (2 equiv.), toluene, 80 °C, 20 h 
No Rxn 
41 
 (2 equiv.), toluene, 80 °C, 20 h 
No Rxn 
42 
 100 °C, 20 h 
1 : 1 : 14* 
43 HMPA, 100 °C, 20 h 
1 : 3.5 : 0 
1 : 3.6 : 0 (duplicate) 
44 DMPU, 100 °C, 20 h 1 : 1.1 : 0 
45 DMI, 100 °C, 20 h 1 : 0.78 : 0 
46 Water, 90 °C, 20 h 1 : 2.4 : 4.7 
47 Pyridine, 110 °C, 36 hb 1 : 1 : 0 
All ratios were measured by 1H NMR. SM refers to the amount of starting material unreacted 
measured by 1H NMR. a2-naphthylsulfonate was installed as leaving group instead of p-
toluenesulfonyl. (*) = low conversion. 
 
With the current results, it was realized that the use of base would not produce selectively the 
desired compound. Even if the 5-membered ring product was the most thermodynamically 
favorable. Therefore, it was necessary to find new conditions that would allow a conformational 
change in the molecule from the S-type to an N-type. (Figure 8) 
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Figure 8. Conformational equilibrium. Coupling constant J1’2’ and percentage of north-type 
conformation of selected nucleosides. 
Calculating the coupling constants J1’2’ of compounds 32, 14, and 33, it was possible to 
determine the conformation expressed as a percentage of the north type conformation40 in 
solution (CDCl3). In the cEt-LNA (33), the anomeric signal appears as a singlet, which means 
that 100 % of the population of 33 molecule is in a northern type conformation (Figure 8). The 
starting material of the cyclization (32) is in a 29% of N-type which compared with the 34% of 
the undesired oxetane 14, showed how the conformational equilibrium in Figure 8 is strongly 
displaced towards S-type conformation. In order to try to change the natural conformation of the 
molecule and favor the N-type conformation, it was decided to try the cyclization in solvents 
with different polarities that could influence the conformational equilibrium. Experimentation 
began with the use of non-protic polar solvents such as DME and DMF. The first solvent gave 
no conversion, and DMF favored the formation of the oxetane product (Table 1, entries 34 and 
35). When 1-methyl-2-pyrrolidinone and DMSO were employed as solvents (entry 36 and 37), 
a better selectivity was achieved without the use of any base. However, when other solvents 
such as sulfoxides and sulfones (entry 38 to 42), no improvement in the reaction selectivity was 
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obtained. The use of HMPA as solvent, afforded a 3.6 : 1 ratio favouring the desired product. 
Other common solvents such as DMPU and DMI did not show improvement compared to the 
result obtained with HMPA (entry 44 and 45). Applying the better conditions for the cyclization  
found in entry 43 to a larger scale, produce 33 in 50% isolated yield.  
Another option that was worth studying is the work developed by Tan where 5'-protected 
nucleosides can be either silylated at 2' or 3'-alcohol by using the appropriate catalyst.41 
Following Tan’s conditions, selective protection of the 3’-OH in 14 to subsequently cyclize to 
obtain the 3’-OTES-(S)-cEt-LNA was tried (scheme 11). Independent of the conditions used, 
only the 2'-OTES protected nucleoside 34 was obtained. Surprisingly, when 14 was treated with 
an excess of TESOTf, 34 was obtained as sole product. Different conditions were tried to 
introduce a TBS group in the remaining 3'-OH, but probably due to the steric hindrance, it was 
not possible to obtain the product forcing us to abandon this approach. 
 
Scheme 11. Selective protection of nucleoside 32 
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3.7 Synopsis 
 
The comparative yields obtained for each one of the reported synthesis are shown in Table II. 
The first generation did not afford the final product, instead, 5 was obtained in 7 steps and 26% 
yield.  Alkylation of aldehyde 5 proved to be difficult giving a complex mixture under different 
conditions, forcing us to abandon this approach. 
The second generation synthesis produced 3’-benzyl-(S)-cEt-LNA 16 in 4% yield. The need of 
an oxidation/reduction sequence in order to obtain the desired isomer 12 as a single product 
reduced the efficiency of the route. Also, the protection of the 3’-alcohol proved to be necessary 
to avoid the formation of the undesired oxetane product.  
The third generation synthesis produced 3’-naphthyl-(S)-cEt-LNA 30 in 2% yield. The use of a 
cuprate as a methyl source provides the alcohol 28 with the desired configuration. However, it 
was still required to protect the 3’-alcohol as a 2-methylnaphthyl ether, which not only allowed 
the exclusive formation of the 5-membered ring, but also gave an easily cleavable protecting 
group compared to the benzyl ether in 16. This approach involves 13 steps and warrants further 
improvement in overall yield.  
The fourth generation affords the desired product in 7% yield in 9 linear steps. The key step of 
this route is the cyclization of 32 in HMPA that affords the (S)-cEt-LNA with the 3’-OH free. 
The use of inexpensive reagents in the synthesis and the reduced number of steps, make the 
fourth generation synthesis in an interesting option for a future scalable production. 
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Table II.  Number of steps, yields and final products of the four synthesis.  
 Number of Steps Yield Product 
 
First generation 
 
7 
 
26% 
 
 
Second generation 
 
15 
 
4% 
 
 
Third generation 
 
13 
 
2% 
 
 
Fourth generation 
 
9 
 
7% 
 
Literature 
Referencea 
14 22% 
 
a Diacetone D-allofuranose as starting material. 
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4 Conclusions 
 
 The synthesis of 5’-O-TBDPS-(S)-cEt-LNA was achieved in 9 steps with 7 % overall 
yield. 
 The combined use of 5-methyluridine as starting material and readily available and 
reasonably priced reagents provides an option for a scalable route to (S)-cEt-LNA. 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
5 Experimental Procedures 
5.1 General Experimental  
All non-aqueous reactions were run in oven (120 °C) or flame-dried glassware under a positive 
pressure of argon, with exclusion of moisture from reagents and glassware, using standard 
techniques for manipulating air-sensitive compounds, unless otherwise stated. Anhydrous 
tetrahydrofuran, diethyl ether, toluene, and dichloromethane were obtained by passing these 
solvents through activated columns of alumina, while all other solvents were used as received 
from chemical suppliers. Reagents were purchased and used without further purification. Yields 
refer to chromatographically and spectroscopically (1H NMR) homogeneous material, unless 
otherwise stated. Reactions were monitored by thin-layer chromatography (TLC) carried out on 
0.25 mm silica plates (SIL 60, G-25, UV254) that were visualized using a UV lamp (254 nm) 
and developed with an aqueous solution of ceric ammonium molybdate, or an ethanolic solution 
of p-anisaldehyde. Flash chromatography42 was performed using SiliaFlash® P60 40-63 μm 
(230-400 mesh) silica gel and all column dimensions are reported as height × diameter in 
centimeters. NMR spectra were recorded on Bruker AV-300, ARX-400, or AV-400 instruments, 
calibrated using residual undeuterated solvent as an internal reference (CHCl3, δ = 7.26 ppm), 
and reported in parts per million relative to tetramethylsilane (TMS δ = 0.00 ppm) as follows: 
chemical shift (multiplicity, coupling constant (Hz), integration). The following abbreviations 
were used to explain multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
br = broad, dd = doublet of doublets, dt = doublet of triplets. High resolution mass spectra 
(HRMS) were recorded at the Centre Régional de Spectrométrie de Masse de l’Université de 
Montréal on an Agilent LC-MSD TOF mass spectrometer by electrospray ionization time of 
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flight reflectron experiments. Specific rotation measurements were recorded on a Perkin-Elmer 
343 Polarimeter and are reported in units of deg·cm3·g-1·dm-1. 
 
5.2 Experimental Section 
5.2.1 First Generation Synthesis 
 
 
(1-((3a'R,4'R,6'R,6a'R)-4'-(hydroxymethyl)tetrahydrospiro[cyclohexane-1,2'-furo[3,4-d]-
[1,3]dioxol]-6'-yl)-5-methylpyrimidine-2,4(1H,3H)-dione) (1). 5-Methylurdine (5.01 g, 19.4 
mmol) was added to a stirred solution of cyclohexanone (30 mL) and p-toluenesulfonic acid 
(0.51 g, 2.5 mmol). The reaction mixture was heated to 50 °C for 40 h, cooled to room 
temperature, then directly purified by flash chromatography (20 × 5.5 cm, 1:1 EtOAc/hexanes) 
to give nucleoside 1 as a white foam (6.37 g, 96 %) Rf = 0.10 (EtOAc). 
1H and 13C NMR data 
match with previously reported data.43  
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1-((3a'S,6'R,6a'R)-4',4'-bis(hydroxymethyl)tetrahydrospiro[cyclohexane-1,2'-furo[3,4-d]-
[1,3]dioxol]-6'-yl)-5-methylpyrimidine-2,4(1H,3H)-dione) (2). Dess-Martin periodinane (1.8 
g, 4.3 mmol) and sodium bicarbonate (1.00 g, 11.9 mmol) were added to a stirred solution of 1 
(1.12 g, 3.30 mmol) in dichloromethane (15 mL). After stirring at room temperature for 3 h, 
ethyl acetate (10 mL) and a 10 % (w/v) solution of Na2S2O3 were added and stirred until a clear 
organic phase was obtained. The layers were separated and the aqueous layer was extracted with 
EtOAc (4 × 5 mL). The combined organic extracts were concentrated under reduced pressure. 
The residue was dissolved in THF (15 mL), and stirred with a 37 % aqueous solution of 
formaldehyde (4.0 mL, 54 mmol), and 1 M NaOH (6 mL, 6 mmol). After 12 h, the reaction 
mixture was cooled to 0 °C and sodium borohydride (0.50 g, 13 mmol) was added. The cooling 
bath was removed and the reaction was allowed to warm to room temperature over a 3 h period. 
The reaction mixture was neutralized via the addition of 1 M HCl, and the resulting solution 
was extracted with dichloromethane (5 × 10 mL). The combined organic extracts were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by 
flash chromatography (15 × 3.5 cm, 9:1 EtOAc/hexanes) to give nucleoside 2 as a white foam 
(620 mg, 51% over 2 steps) Rf = 0.20 (4:1 EtOAc/hexanes). 
1H and 13C NMR data match 
with previously reported data.43  
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((3aS,4S,12R,12aR)-9-methyl-8-oxo-3a,4,5,8,12,12a-hexahydrospiro[4,12-epoxy[1,3]diox-
olo[4,5-e]pyrimido[2,1-b][1,3]oxazocine-2,1'-cyclohexan]-4-yl)methyl trifluoromethane-
sulfonate (3). Pyridine (1.40 mL, 17.2 mmol) and trifluoromethanesulfonic anhydride (1.70 
mL, 10.1 mmol) were added to stirred solution of 2 (1.55 g, 4.21 mmol) in dichloromethane (22 
mL) at 0 °C. After 1 h, water (5 mL) was added and the resulting mixture was stirred for 10 min. 
The layers were separated and the organic layer was washed with 0.5 M HCl (3 × 20 mL) and 
water (10 mL). The organic extracts were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography (14 × 5 cm, 2:8 
EtOAc/hexanes) to give bistriflate nucleoside as a white foam (2.39 g, 90%); Rf = 0.87 (EtOAc). 
DBU (0.38 mL, 2.5 mmol) was added to a stirred solution of bistriflate nucleoside (0.53 mg, 
0.84 mmol) in dry MeCN (6 mL) at room temperature. After stirring for 10 min; 
dichloromethane (15 mL) was added and the organic solution was washed with 0.5 M HCl (5 
mL) and water (5 mL). The organic extracts were dried over Na2SO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash chromatography (8 × 3 cm, EtOAc) 
to give nucleoside 3 as a white foam (340 mg, 83 %) Rf = 0.28 (EtOAc); 
1H NMR (400 MHz, 
CDCl3) δ 7.19 (s, 1H), 5.42 (s, 1H), 5.03 – 4.93 (m, 2H), 4.81 (d, J = 11.2 Hz, 1H), 4.68 (d, J = 
11.1 Hz, 1H), 4.55 (d, J = 12.6 Hz, 1H), 4.20 (d, J = 12.8 Hz, 1H), 2.00 (s, 3H), 1.86 – 1.33 (m, 
10H).; 13C NMR (101 MHz, CDCl3) δ 156.0, 137.2, 115.6, 98.3, 88.2, 86.1, 81.9, 74.9, 72.9, 
35.8, 34.2, 24.9, 23.9, 23.7, 13.6.  
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(3aS,4R,12R,12aR)-4-(hydroxymethyl)-9-methyl-4,5,12,12a-tetrahydrospiro[4,12-epoxy-
[1,3]dioxolo[4,5-e]pyrimido[2,1-b][1,3]oxazocine-2,1'-cyclohexan]-8(3aH)-one (4). 
Tetrabutylammonium nitrite (400 mg, 1.38 mmol) was added to a stirred solution of 3 (0.11 g, 
0.24 mmol) in THF (5 mL) at room temperature. After 20 h, water (10 mL) and dichloromethane 
(5 mL) were added, the layers were separated and the resulting solution was extracted with 
dichloromethane (5 × 5 mL). The combined organic extracts were dried over Na2SO4, filtered, 
and concentrated under reduced pressure. The residue was purified by flash chromatography 
(14 × 2 cm, 5 % MeOH/EtOAc) to give nucleoside 4 as a white foam (71 mg, 85%) Rf = 0.10 
5% MeOH/EtOAc); 1H NMR (300 MHz, 1:1 MeOH-d4/CDCl3) δ 7.19 (s, 1H), 5.36 (s, 1H), 
4.93 (q, J = 5.6 Hz, 2H), 4.66 (d, J = 12.9 Hz, 1H), 4.18 (d, J = 12.9 Hz, 1H), 4.00 (d, J = 12.1 
Hz, 1H), 3.85 (d, J = 12.1 Hz, 1H), 3.01 (s, 1H), 1.98 (s, 3H), 1.79 – 1.32 (m, 10H); 13C NMR 
(75 MHz, 1:1 MeOH-d4/CDCl3) δ 172.8, 157.1, 139.0, 119.3, 114.0, 97.87, 90.6, 85.5, 81.3, 
76.8, 59.9, 35.4, 33.8, 24.5, 23.4, 23.2, 12.4. HRMS (ESI) calc’d for C17H23N2O6 [M+H]+  m/z 
= 351.1551, found 351.1556; calc’d for C17H22N2NaO6 [M+Na]+ m/z = 373.137, found 373.136. 
 
(3aS,4R,12R,12aR)-9-methyl-8-oxo-3a,4,5,8,12,12a-hexahydrospiro[4,12-epoxy[1,3]di-
oxolo[4,5-e]pyrimido[2,1-b][1,3]oxazocine-2,1'-cyclohexane]-4-carbaldehyde (5). Dess 
Martin periodinane (60 mg, 0.14 mmol) and sodium bicarbonate (20 mg, 0.23 mmol) were added 
to a stirred solution of nucleoside 4 (32 mg, 0.091 mmol) in dichloromethane (1 mL). After 2 h, 
ethyl acetate (2 mL) and 10 % (w/v) solution of Na2S2O3 were added and stirred until a clear 
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organic phase was obtained. The layers were separated and the aqueous layer was extracted with 
EtOAc (4 × 2 mL). The combined organic extracts were dried over Na2SO4, filtered, and 
concentrated under reduced pressure. The residue was purified by flash chromatography ( 8 × 1 
cm, 1:1 acetone/dichloromethane) to give nucleoside 5 as a white powder (27 mg, 85% over 2 
steps) Rf = 0.17 (1:1 acetone/dichloromethane); 
1H NMR (300 MHz, 1:1 MeOH-d4/CDCl3) δ 
5.31 (d, J = 4.3 Hz, 1H), 4.78 – 4.64 (m, J = 5.7 Hz, 3H), 4.58 – 4.41 (m, J = 18.4, 12.8 Hz, 
1H), 4.22 (s, 4H), 4.10 – 3.96 (m, 1H), 3.23 (s, 1H), 3.15 (d, J = 5.6 Hz, 2H), 3.13 – 3.07 (m, 
1H), 1.74 (s, 3H), 1.57 – 0.94 (m, 10H). 13C NMR (75 MHz, 1:1 MeOH-d4/CDCl3) δ 172.83, 
172.80, 157.14, 138.85, 119.46, 119.40, 113.99, 113.86, 98.20, 98.07, 96.30, 96.11, 91.67, 
91.52, 85.47, 85.18, 81.95, 81.85, 81.61, 77.16, 74.54, 74.42, 55.31, 54.73, 35.61, 35.56, 33.86, 
33.75, 24.60, 23.70, 23.57, 23.39, 23.29, 12.62. 
 
 
1-((3a'S,4'S,6'R,6a'R)-4'-(((tert-butyldiphenylsilyl)oxy)methyl)-4'-(hydroxymethyl)tetra-
hydrospiro[cyclohexane-1,2'-furo[3,4-d][1,3]dioxol]-6'-yl)-5-methylpyrimidine-2,4-
(1H,3H)-dione (6): tert-Butyldiphenylsilyl chloride (0.24 mL, 0.92 mmol) and imidazole (62 
mg, 0.92 mmol) were added to a stirred, 0 °C solution of nucleoside 2 (0.30 g, 0.83 mmol) in 
DMF (4 mL).  After 6 h, 1 M HCl (10 mL) was added to the reaction mixture, the layers were 
separated and the resulting solution was extracted with Et2O (3 × 15 mL). The combined organic 
extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue 
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was purified by flash chromatography (14 × 3 cm, 3:7 EtOAc/hexanes) to give nucleoside 6 as 
a white foam (343 mg, 68%) Rf = 0.34 (4:6 EtOAc/hexanes);  
1H NMR (400 MHz, CDCl3) δ 
8.56 (s, 1H), 7.74 – 7.62 (m, 4H), 7.48 – 7.34 (m, 6H), 7.09 (s, 1H), 5.25 – 5.16 (m, 2H), 4.96 
(d, J = 5.9 Hz, 1H), 4.01 – 3.90 (m, 3H), 3.68 (d, J = 10.7 Hz, 1H), 3.37 (dd, J = 7.8, 4.0 Hz, 
1H), 1.92 (s, 3H), 1.73 – 1.31 (m, 10H), 1.06 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 163.6, 
150.5, 139.5, 135.8, 133.3, 129.9, 127.8, 127.8, 115.0, 111.2, 96.6, 89.2, 82.0, 81.1, 65.8, 63.80, 
36.9, 34.5, 26.9, 25.0, 24.0, 23.5, 19.4, 12.5; LRMS (ESI) calc’d for C33H42N2O7NaSi [M+Na]+ 
m/z = 629.27, found 629.3. 
 
 
(3aS,4S,12R,12aR)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-9-methyl-4,5,12,12a-tetrahy-
drospiro[4,12-epoxy[1,3]dioxolo[4,5-e]pyrimido[2,1-b][1,3]oxazocine-2,1'-cyclohexan]-8-
(3aH)-one) (7). Pyridine (0.80 mL, 10 mmol) and trifluoromethanesulfonic anhydride (0.90 mL, 
5.3 mmol) were added to a stirred solution of 6 (0.29 g, 0.47 mmol) in dichloromethane (4 mL) 
at 0 °C. After 40 min, water (2 mL) and dichloromethane (10 mL) were added and stirred for 
10 min. The layers were separated and the organic layer was washed with 0.5 M HCl (3 × 5 mL) 
and water (5 mL). The organic extracts were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography (10 × 3 cm, 2:8 
EtOAc/hexanes) to give nucleoside 6a as a white foam (329 mg, 93%) Rf = 0.53 (4:6 
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 9.60 (s, 1H), 7.77 – 7.63 (m, 4H), 7.51 – 7.35 
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(m, 6H), 6.97 (s, 1H), 5.32 (d, J = 2.6 Hz, 1H), 5.17 (dd, J = 6.4, 2.6 Hz, 1H), 4.97 (d, J = 9.8 
Hz, 1H), 4.90 (d, J = 5.3 Hz, 1H), 4.83 (d, J = 9.8 Hz, 1H), 1.94 (s, 3H), 1.75 – 1.25 (m, 12H), 
1.08 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 164.1, 150.6, 138.7, 135.9, 135.8, 133.1, 132.9, 
129.9, 127.9, 127.8, 115.5, 111.8, 94.4, 87.7, 83.7, 81.4, 75.3, 62.5, 35.7, 33.9, 26.9, 25.0, 23.9, 
23.5, 19.3, 12.3; LRMS (ESI) calc’d for C34H41F3N2O9NaSSi [M+Na]+ m/z = 761.22, found 
761.1. DBU (0.13 mL, 0.87 mmol) was added to a stirred solution of 6a (0.33 g, 0.44 mmol) in 
dry MeCN (2 mL) at room temperature. After 10 min, dichloromethane (5 mL) was added and 
the resulting solution was washed with 0.5 M HCl (2 × 2 mL) and water (2 mL). The organic 
extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue 
was purified by flash chromatography (10 × 3 cm, EtOAc) to give nucleoside 7 as a white foam 
(260 mg, 99%) Rf = 0.32 (EtOAc); 
1H NMR (400 MHz, CDCl3) δ 7.71 – 7.59 (m, 4H), 7.49 – 
7.35 (m, 6H), 7.16 (s, 1H), 5.29 (s, 1H), 4.93 (dd, J = 14.4, 5.6 Hz, 2H), 4.72 (d, J = 12.7 Hz, 
1H), 4.18 (d, J = 12.7 Hz, 1H), 4.07 (d, J = 10.7 Hz, 1H), 3.73 (d, J = 10.7 Hz, 1H), 1.99 (s, 3H), 
1.68 – 1.47 (m, 10H), 1.05 (s, 9H).; 13C NMR (101 MHz, CDCl3) δ 172.0, 156.8, 137.5, 135.7, 
135.6, 132.6, 132.5, 130.1, 128.0, 127.9, 120.3, 114.5, 98.4, 91.0, 85.9, 81.8, 62.0, 36.0, 34.5, 
26.8, 25.0, 23.9, 23.8, 19.3, 13.6; LRMS (ESI) calc’d for C33H40N2O6Si [M+H]+ m/z = 589.27, 
found 589.3. 
 
 
 
 
48 
 
5.2.2 Second Generation Synthesis 
 
 
1-((3a'S,4'S,6'R,6a'R)-4'-(hydroxymethyl)-4'-((trityloxy)methyl)tetrahydrospiro[cyclo-
hexane-1,2'-furo[3,4-d][1,3]dioxol]-6'-yl)-5-me-thylpyrimidine-2,4(1H,3H)-dione (8). 
Trityl chloride (4.53 g, 16.2 mmol), 4-dimethylaminopyridine (0.14 g, 1.1 mmol) and 
triethylamine (3.00 mL, 21.5 mmol) were added to a stirred solution of nucleoside 2 (3.98 g, 
10.8 mmol) in anhydrous DMF (55 mL). After 12 h, EtOAc (50 mL) and 1 M HCl (50 mL) 
were added. The layers were separated and the aqueous layer was extracted with EtOAc (3 × 50 
mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography (20 × 4 cm, 4:6 
EtOAc/hexanes) to give nucleoside 8 as a white foam (4.69 g, 71%) Rf = 0.20 (2:3 
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 9.45 (s, 1H), 7.55 – 7.43 (m, 6H), 7.34 – 7.27 
(m, J = 8.4, 6.4 Hz, 6H), 7.25 – 7.15 (m, J = 7.2 Hz, 3H), 5.38 (d, J = 4.4 Hz, 1H), 5.20 – 5.13 
(m, J = 6.3, 4.3 Hz, 1H), 5.01 (d, J = 6.3 Hz, 1H), 3.93 – 3.82 (m, 2H), 3.47 – 3.35 (m, 2H), 3.20 
(d, J = 9.9 Hz, 1H), 1.90 (s, 3H), 1.69 – 1.29 (m, 10H); 13C NMR (101 MHz, CDCl3) δ 164.0, 
150.7, 143.8, 139.2, 128.8, 127.9, 127.2, 115.0, 111.2, 95.6, 88.9, 87.1, 82.4, 81.1, 65.6, 63.3, 
36.6, 34.4, 25.0, 23.9, 23.6, 12.4; [α]D25 = ˗2 (10 mg/mL, CH2Cl2). 
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1-((3a'S,4'R,6'R,6a'R)-4'-(((tert-butyldiphenylsilyl)oxy)methyl)-4'-((trityloxy)methyl)-
tetrahydrospiro[cyclohexane-1,2'-furo[3,4-d][1,3]dioxol]-6'-yl)-5-ethylpyrimidine-2,4-
(1H,3H)-dione (9). tert-Butyldiphenylsilyl chloride (6.2 mL, 24 mmol) and imidazole (1.51 g, 
22.2 mmol) were added to a stirred solution of nucleoside 8 (10.4 g, 17.1 mmol) in anhydrous 
dichloromethane (150 mL).  After 24 h, 1 M HCl (50 mL) was added to the reaction, the layers 
were separated and the resulting solution was extracted with dichloromethane (3 × 40 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography (15 × 4 cm, 1:4 EtOAc/hexanes) to 
give nucleoside 9 as a white foam (12.5 g, 90%), Rf = 0.60 (2:3 EtOAc/hexanes); 
1H NMR (400 
MHz, CDCl3) δ 8.80 (s, 1H), 7.72 – 7.63 (m, 4H), 7.54 – 7.24 (m, 21H), 6.02 (s, 1H), 4.85 (s, 
2H), 4.12 (d, J = 11.1 Hz, 1H), 3.78 (d, J = 11.0 Hz, 1H), 3.53 (d, J = 9.7 Hz, 1H), 3.15 (d, J = 
9.7 Hz, 1H), 1.78 – 1.33 (m, 13H), 1.14 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 163.8, 150.3, 
143.8, 135.9, 135.7, 135.5, 132.9, 132.4, 130.2, 130.2, 128.7, 128.1, 128.1, 127.9, 127.1, 114.9, 
111.3, 89.8, 88.1, 86.9, 83.9, 81.5, 67.2, 62.4, 36.9, 34.9, 27.2, 25.0, 23.9, 23.7, 19.5, 12.1; 
HRMS (ESI) calc’d for C52H56N2O7Si [M+H]+ m/z = 871.3749, found 871.37506. 
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1-((3a'S,4'R,6'R,6a'R)-4'-(((tert-butyldiphenylsilyl)oxy)methyl)-4'-(hydroxymethyl)tetra-
hydrospiro[cyclohexane-1,2'-furo[3,4-d][1,3]dioxol]-6'-yl)-5-methylpyrimidine-2,4-
(1H,3H)-dione (10). Trifluoroacetic acid (0.83 mL, 11 mmol) was added in three portions, with 
1 minute stirring between additions them to a stirred solution of nucleoside 9 (0.91 mg, 1.1 
mmol) in dichloromethane (7.5 mL). After 10 min, the reaction mixture was neutralized via 
addition of a saturated sodium bicarbonate solution. The layers were separated and the aqueous 
layer was extracted with dichloromethane (4 × 5 mL).  The combined organic extracts were 
dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified 
by flash chromatography (16 × 3 cm, 3:7 EtOAc:hexanes) to give nucleoside 10 as  a white 
foam (625 mg, 95% based on recovered starting material). Rf = 0.35 (1:1 EtOAc/hexanes); 
1H 
NMR (400 MHz, CDCl3) δ 9.32 (s, 1H), 7.68 – 7.60 (m, 4H), 7.46 – 7.32 (m, 6H), 7.28 (s, 1H), 
6.02 (s, 1H), 4.87 (s, 2H), 4.01 (d, J = 11.2 Hz, 1H), 3.95 (d, J = 11.1 Hz, 1H), 3.82 (d, J = 12.1 
Hz, 1H), 3.73 (d, J = 12.0 Hz, 1H), 2.35 (s, 1H), 1.89 – 1.81 (m, 2H), 1.71 – 1.51 (m, 9H), 1.45 
– 1.35 (m, 2H), 1.10 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 163.9, 150.4, 136.2, 135.6, 135.3, 
132.9, 132.4, 130.1, 130.0, 127.9, 127.9, 115.7, 111.4, 90.4, 88.3, 84.1, 81.4, 66.2, 62.8, 36.4, 
34.3, 27.1, 24.9, 24.1, 23.6, 19.4, 11.9; HRMS (ESI) calc’d for C33H43N2O7Si [M+H]+ m/z =  
607.2834, found 607.28448. 
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1-((3a'S,4'S,6'R,6a'R)-4'-(((tert-butyldiphenylsilyl)oxy)methyl)-4'-((S)-1-hydroxyethyl)-
tetrahydrospiro[cyclohexane-1,2'-furo[3,4-d][1,3]dioxol]-6'-yl)-5-methylpyrimidine-2,4-
(1H,3H)-dione (11). Dess-Martin periodinane (0.68 g, 1.6 mmol) and sodium bicarbonate (0.5 
g, 6 mmol) were added to a stirred solution of nucleoside 10 (0.75 g, 1.2 mmol) in anhydrous 
dichloromethane (7.0 mL). After 1 h, dichloromethane (7 mL) and a 10 % (w/v) aqueous 
solution of Na2S2O3 were added and stirred until a clear organic phase was obtained. The layers 
were separated and the aqueous layer was extracted with dichloromethane (4 × 10 mL). The 
combined organic extracts were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The residue was dissolved in dry toluene (6.0 mL), cooled to 0 °C and mixed with 2 
M AlMe3 in hexanes (1.9 mL, 3.8 mmol). After 1 h, the reaction mixture was diluted with 1 M 
HCl, then the layers were separated and the aqueous layer was extracted with dichloromethane 
(4 × 5 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash chromatography (15 × 3 cm, 3:7 
EtOAc/hexanes) to give nucleoside 11 as a white foam (521 mg, 68%) Rf = 0.20 (2 % MeOH in 
dichloromethane); 1H NMR (400 MHz, CDCl3) δ 8.61 (s, 1H), 7.69 – 7.58 (m, J = 15.4, 6.5, 1.6 
Hz, 4H), 7.49 – 7.35 (m, 7H), 6.14 (d, J = 5.3 Hz, 1H), 4.95 (d, J = 6.3 Hz, 1H), 4.79 (dd, J = 
6.3, 5.4 Hz, 1H), 4.25 – 4.16 (m, 1H), 4.13 (d, J = 11.2 Hz, 1H), 3.96 (d, J = 11.2 Hz, 1H), 2.72 
(s, 1H), 1.92 – 1.23 (m, 16H), 1.13 (s, 12H); 13C NMR (101 MHz, CDCl3) δ 163.6, 150.4, 135.6, 
135.4, 135.3, 133.0, 132.2, 130.4, 130.3, 128.3, 128.2, 115.9, 111.7, 89.3, 89.1, 84.1, 81.5, 68.1, 
64.4, 37.0, 34.8, 27.3, 25.0, 24.2, 23.8, 19.6, 16.4, 11.93; HRMS (ESI) calc’d for C34H45N2O7Si 
[M+H]+ m/z = 621.29905, found 621.30039; calc’d for C34H44N2NaO7Si [M+Na]+ m/z = 
643.281, found 643.28199. [α]D25 = ˗1 (10 mg/mL, CH2Cl2) 
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1-((3a'S,4'S,6'R,6a'R)-4'-(((tert-butyldiphenylsilyl)oxy)methyl)-4'-((R)-1-hydroxyethyl)-
tetrahydrospiro[cyclohexane-1,2'-furo[3,4-d][1,3]dioxol]-6'-yl)-5-methylpyrimidine-2,4-
(1H,3H)-dione (12). Dess-Martin periodinane (0.46 g, 1.1 mmol) and sodium bicarbonate (0.45 
g 5.3 mmol) were added to a stirred solution of nucleoside 11 (0.52 g, 0.84 mmol) in anhydrous 
dichloromethane (4.5 mL). After 1 h, dichloromethane (5 mL) and a 10 % (w/v) aqueous 
solution of Na2S2O3 were added and stirred until a clear organic phase was obtained. The layers 
were separated and the aqueous layer was extracted with dichloromethane (4 × 4 mL). The 
combined organic extracts were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The residue was dissolved in dry THF (4.5 mL) and stirred with lithium aluminum 
hydride (108 mg, 2.81 mmol) at ˗78 °C. After 1 h, the reaction mixture was diluted with ethyl 
acetate (5 mL) and HCl 1 M (5 mL). The layers were separated and the aqueous layer was 
extracted with dichloromethane (3 × 4 mL). The combined organic extracts were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography (15 × 3 cm, 4:6 EtOAc/hexanes) to give nucleoside 12 as a white foam (520 
mg, quantitative), Rf = 0.42 (2 % MeOH in dichlorometane); 
1H NMR (400 MHz, CDCl3) δ 
9.11 (s, 1H), 7.67 – 7.59 (m, J = 8.0, 7.3, 1.5 Hz, 4H), 7.48 – 7.33 (m, 7H), 6.12 (d, J = 5.5 Hz, 
1H), 4.83 (t, J = 5.7 Hz, 1H), 4.73 (d, J = 6.0 Hz, 1H), 4.15 (d, J = 6.5 Hz, 1H), 3.99 (d, J = 11.3 
Hz, 1H), 3.91 (d, J = 11.3 Hz, 1H), 1.89 – 1.30 (m, J = 116.3, 3.7 Hz, 14H), 1.17 (d, J = 6.5 Hz, 
3H), 1.12 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 163.9, 150.5, 135.8, 135.6, 135.4, 132.8, 
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132.1, 130.4, 130.3, 128.2, 128.1, 115.4, 111.5, 89.8, 89.8, 83.7, 81.7, 69.1, 65.5, 37.1, 34.6, 
27.3, 25.0, 24.1, 23.7, 19.5, 17.6, 11.9; HRMS (ESI) calc’d for C34H45N2O7Si [M+H]+ m/z = 
621.29905, found 621.29981; calc’d for C34H44N2NaO7Si [M+Na]+ m/z = 643.281, found 
643.28169; [α]D25 = ˗8° (10 mg/mL, CH2Cl2)  
 
 
(R)-1-((2R,3S,4R,5R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3,4-dihydroxy-5-(5-me-
thyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)ethyl methanesulfo-
nate (13). Methanesulfonyl chloride (50 µL, 0.18 mmol) and 4-dimethylaminopyridine (10 mg, 
0.082 mmol) were added to a stirred solution of nucleoside 12 (0.25 g, 0.084 mmol) in 
anhydrous pyridine (2 mL) at 0 °C. The reaction was stirred at room temperature for 12 h, and 
then diluted with 1 M HCl (3 mL) and EtOAc (3 mL). The layers were separated and the aqueous 
layer was extracted with EtOAc (4 × 4 mL). The combined organic extracts were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash 
chromatography (3:7 EtOAc/hexanes) to give nucleoside 12a (240 mg, 85%), Rf = 0.60 (15 × 
2.5 cm, 5 % MeOH in dichlorometane); 1H NMR (400 MHz, CDCl3) δ 8.90 (s, 1H), 7.67 – 7.57 
(m, 4H), 7.50 – 7.36 (m, 7H), 6.13 (d, J = 5.6 Hz, 1H), 5.00 (q, J = 6.5 Hz, 1H), 4.87 – 4.82 (m, 
1H), 4.58 (d, J = 5.5 Hz, 1H), 3.99 (s, 2H), 2.98 (s, 3H), 1.87 – 1.33 (m, 17H), 1.12 (s, 8H); 13C 
NMR (101 MHz, CDCl3) δ 163.6, 150.5, 135.7, 135.4, 135.3, 130.7, 130.5, 128.4, 128.3, 115.4, 
111.8, 89.5, 88.9, 83.4, 81.0, 80.8, 64.3, 38.4, 37.2, 34.8, 27.3, 24.9, 24.1, 23.7, 19.5, 18.2, 12.1; 
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HRMS (ESI) calc’d for C35H47N2O9SSi [M+H]+ m/z = 699.2766, found 699.27731; calc’d for 
C35H46N2NaO9SSi [M+Na]
+ m/z = 721.25855, found 721.25913; [α]D25 = ˗16 (10 mg/mL, 
CH2Cl2). A 37 % aqueous solution of HCl (1.50 mL, 17.5 mmol) was added to a stirred solution 
of nucleoside 12a (0.15 g, 0.22 mmol) in THF (1 mL) and MeOH (2 mL). After 12 h, the reaction 
was neutralized via addition of saturated sodium bicarbonate solution. The layers were separated 
and the aqueous layer was extracted with dichloromethane (5 × 4 mL). The combined organic 
extracts were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue 
was purified by flash chromatography (2:1 EtOAc/hexanes) to give nucleoside 13 as a white 
foam (86 mg, 63%), Rf = 0.28 (15 × 1.5 cm, 4:1 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) 
δ 10.19 (s, 1H), 7.69 – 7.57 (m, 4H), 7.49 – 7.32 (m, 7H), 6.12 (d, J = 7.5 Hz, 1H), 5.37 – 5.14 
(m, J = 6.4 Hz, 2H), 4.58 (dd, J = 7.6, 5.4 Hz, 1H), 4.43 (d, J = 5.3 Hz, 1H), 3.98 – 3.87 (m, J = 
7.4 Hz, 2H), 3.62 (s, 1H), 3.01 (s, 3H), 1.40 (d, J = 6.5 Hz, 3H), 1.35 (s, 3H), 1.10 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 163.8, 152.1, 136.0, 135.6, 135.3, 132.8, 131.86, 130.6, 130.3, 128.3, 
128.2, 111.4, 89.6, 81.5, 74.7, 72.6, 64.1, 38.3, 29.8, 27.3, 19.6, 18.3, 11.9; HRMS (ESI) calc’d 
for C29H39N2O9SSi [M+H]
+ m/z = 619.214, found 619.21509; calc’d for C29H38N2NaO9SSi 
[M+Na]+ m/z = 641.19595, found 641.19717. 
 
 
1-((1S,3R,4R,5S,7S)-1-(((tert-butyldiphenylsilyl)oxy)methyl)-4-hydroxy-7-methyl-2,6-di-
oxabicyclo[3.2.0]heptan-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (14). Potassium 
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carbonate (3 mg, 0.02 mmol) was added to a stirred solution of 13 (9.2 mg, 0.014 mmol) in 
methanol (2 mL). After stirring at 70 °C for 24 h, the solution was concentrated under reduced 
pressure and the solid residue was dissolved in MeOH:CH2Cl2 (5 %). The solution was passed 
through a silica gel pad and eluted with MeOH:CH2Cl2 (5%). The obtained solution was 
concentrated under reduced pressure. The residue did not required further purification and 
provided nucleoside 8 as a white foam (7 mg, 90%), Rf = 0.21 (3:1 EtOAc/hexanes); 
1H NMR 
(300 MHz, CDCl3) δ 8.39 (s, 1H), 7.73 – 7.57 (m, 4H), 7.52 – 7.34 (m, 6H), 7.19 (s, 1H), 6.35 
(d, J = 6.7 Hz, 1H), 4.96 (d, J = 4.8 Hz, 1H), 4.77 (q, J = 6.6 Hz, 1H), 4.14 – 4.03 (m, 1H), 3.96 
(q, J = 11.6 Hz, 2H), 3.03 (d, J = 10.1 Hz, 1H), 1.66 (s, 3H), 1.36 (d, J = 6.7 Hz, 3H), 1.08 (s, 
9H); 13C NMR (75 MHz, CDCl3) δ 163.3, 150.8, 135.6, 135.4, 132.9, 132.3, 130.4, 130.3, 128.2, 
128.1, 112.1, 89.0, 88.0, 86.4, 81.7, 76.1, 61.5, 27.0, 19.5, 18.1, 12.2; HRMS (ESI) calc’d for 
C28H35N2O6Si [M+H]
+ m/z = 523.22589, found 523.22523; calc’d for C28H34N2NaO6Si 
[M+Na]+ m/z = 545.20783, found 545.2074. 
 
(1R)-1-((3aS,4R,6R,6aR)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-6-(5-methyl-2,4-dioxo-
3,4-dihydropyrimidin-1(2H)-yl)-2-phenyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)ethyl me-
thanesulfonate (15). Camphorsulfonic acid (2 mg, 0.008 mmol) and benzaldehyde dimethyl 
acetal (0.1 mL, 0.6 mmol) were added to a stirred solution of 13 (38 mg, 0.062 mmol) in 1,2-
dichloroethane (0.3 mL). After refluxing for 1 h, the mixture was cooled to room temperature 
and diluted with dichloromethane (1 mL).  The crude mixture was pre-adsorbed on silica gel 
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and purified by flash chromatography (14 × 1 cm, 3:7 EtOAc/hexanes) to give an 1:1 mixture 
of diastereomers 15, based on the integration of the signals at 5.97 and 6,19 ppm, as a white 
foam (36 mg, 82%), Rf = 0.46 (4:6 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 7.71 – 7.29 
(m, 15H), 7.06 (d, J = 6.7 Hz, 1H), 6.19 (d, J = 4.9 Hz, 1H), 5.97 (d, J = 6.5 Hz, 1H), 5.10 – 
4.92 (m, 2H), 4.82 (d, J = 6.1 Hz, 1H), 4.73 (d, J = 6.0 Hz, 1H), 4.07 – 3.92 (m, 2H), 3.55 (d, J 
= 4.9 Hz, 3H), 1.62 (d, 3H), 1.36 (d, J = 6.5 Hz, 3H), 1.11 (d, J = 7.2 Hz, 9H).; 13C NMR (101 
MHz, CDCl3) δ 138.1, 137.9, 135.7, 135.7, 135.5, 135.4, 135.2, 134.9, 134.2, 132.3, 132.1, 
131.7, 130.7, 130.6, 130.3, 130.2, 128.9, 128.8, 128.4, 128.3, 128.3, 128.3, 128.1, 127. 9, 127.8, 
127.0, 127.0, 125.9, 125.7, 108.2, 107.9, 89.8, 84.8, 83.5, 83.5, 80.9, 80.7, 64.3, 64.2, 57.7, 38.4, 
38.1, 27.3, 27.3, 19.5, 19.4, 18.2, 18.1, 13.0, 13.0; HRMS (ESI) calc’d for C36H43N2O9SSi 
[M+H]+ m/z = 707.2453, found 707.24234. 
 
1-((1S,3R,4R,6S,7S)-7-(benzyloxy)-1-(((tert-butyldiphenylsilyl)oxy)methyl)-6-methyl-2,5-
dioxabicyclo[2.2.1]heptan-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (16). Titanium 
chloride (28 µL, 0.25 mmol) was added dropwise to a stirred solution of sodium 
cyanoborohydride (16 mg, 0.25 mmol) and nucleoside 15 (36 mg, 0.051 mmol) in dry 
acetonitrile (0.5 mL) at 0 °C. After 1 h, the reaction mixture was diluted with saturated sodium 
bicarbonate (1 mL) and dichloromethane (1 mL). The layers were separated and the aqueous 
layer was extracted with dichloromethane (4 × 1 mL). The combined organic extracts were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. The crude solid was dissolved 
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in dichloromethane and passed through a silica gel pad and eluted with 5% MeOH:CH2Cl2. The 
obtained solution was concentrated under reduced pressure. The crude solid was dissolved in 
MeOH (1 mL) and mixed with K2CO3 (6 mg, 0.04 mmol). After refluxing for 2 h, the solution 
was concentrated under reduced pressure and the solid residue was dissolved in 5% 
MeOH:CH2Cl2. The solution was passed through a silica gel pad and eluted with 5% 
MeOH:CH2Cl2. The obtained solution was concentrated under reduced pressure. The residue 
did not required further purification and provide nucleoside 16 as a white foam (23 mg, 73% 
over 2 steps), Rf = 0.48 (1:1 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 8.47 (s, 1H), 7.74 
– 7.65 (m, 4H), 7.49 – 7.26 (m, 13H), 5.64 (s, 1H), 4.67 (d, J = 11.3 Hz, 1H), 4.64 (s, 1H), 4.49 
(d, J = 11.3 Hz, 1H), 4.15 – 3.95 (m, 4H), 1.68 (s, 3H), 1.25 (d, J = 6.6 Hz, 4H), 1.10 (s, 9H); 
13C NMR (101 MHz, CDCl3) δ 163.7, 149.7, 136.9, 135.7, 135.5, 134.6, 132.9, 132.4, 130.2, 
128.6, 128.2, 128.1, 128.0, 127.9, 110.4, 89.6, 87.4, 81.2, 72.5, 59.3, 27.0, 26.7, 19.6, 16.5, 12.4. 
 
 
5.2.3 Third Generation Synthesis 
 
 
1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2-(naphthalen-2-yl)tetrahydrofuro[3,4-d][1,3]di-
oxol-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (17). Naphthaldehyde dimethyl acetal (250 
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mg, 1.23 mmol) and camphorsulphonic acid (12 mg, 0.05 mmol) were added to a stirred solution 
of 5-methyluridine (120 mg, 0.465 mmol) in anhydrous 1,2-dichloroethane (2 mL). The reaction 
was heated to reflux for 2 h, cooled to room temperature, and mixed with solid sodium 
bicarbonate (50 mg). The filtrate was evaporated under reduced pressure. The residue was 
purified by flash chromatography (15 × 1.5 cm, 7:3 EtOAc:hexanes) to give 17 as a mixture of 
diastereomers  (156 mg, 85%); 1H NMR (300 MHz, CDCl3) δ 9.27 (s, 2H), 8.00 – 7.78 (m, 7H), 
7.66 – 7.46 (m, 5H), 7.16 – 7.07 (m, 2H), 6.27 (s, 1H), 6.17 (s, 1H), 5.69 – 5.62 (m, 2H), 5.33 
– 5.27 (m, 1H), 5.26 – 5.13 (m, 3H), 4.50 (q, J = 3.2 Hz, 1H), 4.37 (q, J = 3.5 Hz, 1H), 4.07 – 
3.82 (m, 3H), 3.25 (s, 2H), 1.97 – 1.85 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 163.9, 163.9, 
150.7, 150.7, 139.5, 139.0, 134.2, 134.1, 133.3, 133.2, 133.0, 132.9, 128.7, 128.7, 128.5, 128.5, 
127.9, 127.9, 127.0, 126.9, 126.7, 126.6, 126.6, 126.6, 123.6, 111.6, 111.5, 108.1, 104.5, 96.5, 
95.7, 86.9, 85.3, 84.2, 83.6, 81.7, 80.2, 62.9, 62.8, 51.0, 12.5, 12.4; HRMS (ESI) calc’d for 
C21H21N2O6 [M+H]
+ m/z = 397.13941, found 397.13953; calc’d for C21H20N2NaO6 [M+Na]+ 
m/z = 419.12136, found 419.1215. 
 
 
1-((3aR,4R,6aS)-6,6-bis(hydroxymethyl)-2-(naphthalen-2-yl)tetrahydrofuro[3,4-d][1,3]-
dioxol-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (18). Dess-Martin periodinane (0.18 g, 
0.43 mmol) and sodium bicarbonate (80 mg, 0.95 mmol) were added to a stirred solution of 17 
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(0.13 g, 0.32 mmol) in dichloromethane (2 mL). After stirring at room temperature for 2 h, ethyl 
acetate (2 mL) and a 10 % (w/v) solution of Na2S2O3 were added and stirred until a clear organic 
phase was obtained. The layers were separated and the aqueous layer was extracted with EtOAc 
(4 × 2 mL). The combined organic extracts were concentrated under reduced pressure. The 
residue was dissolved in THF (2 mL), and stirred with a 37 % aqueous solution of formaldehyde 
(0.28 mL, 3.8 mmol), and 1 M NaOH (0.5 mL, 0.5 mmol). After 6 h, the reaction mixture was 
cooled to 0°C and sodium borohydride (41 mg, 1.1 mmol) was added. The cooling bath was 
removed and stirring was continued for 10 h at room temperature. The reaction mixture was 
neutralized via the addition of 1 M HCl, and the resulting solution was extracted with 
dichloromethane (5 × 4 mL). The combined organic extracts were dried over Na2SO4, filtered, 
and concentrated under reduced pressure. The residue was purified by flash chromatography 
(10 × 1.5 cm, 9:1 EtOAc/hexanes) to give nucleoside 18 as a white foam (21 mg, 15 % over 2 
steps) Rf = 0.20 (4:1 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 9.18 (s, 1H), 8.06 – 7.77 
(m, 4H), 7.70 – 7.42 (m, 3H), 7.19 (s, 1H), 6.16 (s, 1H), 5.72 (d, J = 3.7 Hz, 1H), 5.47 – 5.37 
(m, 1H), 5.21 (d, J = 7.0 Hz, 1H), 3.97 – 3.73 (m, 4H), 1.90 (s, 3H). HRMS (ESI) calc’d for 
C22H23N2O7 [M+H]
+ m/z = 427.14998, found 427.15169; calc’d for C22H22N2NaO7 [M+Na]+ 
m/z = 449.13192, found 449.13346. 
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1-((2R,3R,4S,5R)-3-hydroxy-5-(hydroxymethyl)-4-(naphthalen-2-ylmethoxy)tetrahydro-
furan-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (19). Titanium chloride (2.55 mL, 23.2 
mmol) was added dropwise to a stirred solution of sodium cyanoborohydride (1.46 g, 23.2 
mmol) and nucleoside 17 (1.84 g, 4.63 mmol) in dry acetonitrile (100 mL) at 0 °C. After 2 h,  
the reaction was diluted with saturated sodium bicarbonate (30 mL) and dichloromethane (30 
mL). The layers were separated and the aqueous layer was extracted with dichloromethane (4 × 
20 mL). The combined organic extracts were dried over Na2SO4, filtered, and concentrated 
under reduced pressure. The residue was purified by flash chromatography (15 × 3 cm, 4:1 
EtOAc/hexanes) to give nucleoside 19 as a white foam (1.74 g, 94%), Rf = 0.37 (EtOAc); 
1H 
NMR (300 MHz, CDCl3) δ 9.72 (s, 1H), 7.87 – 7.71 (m, 4H), 7.51 – 7.38 (m, 3H), 7.28 (s, 1H), 
5.65 (d, J = 5.1 Hz, 1H), 4.87 – 4.72 (m, 2H), 4.55 – 4.45 (m, 1H), 4.28 – 4.20 (m, 1H), 4.20 – 
4.13 (m, 1H), 3.92 – 3.81 (m, 1H), 3.70 – 3.58 (m, 1H), 3.41 (s, 1H), 1.79 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 164.2, 151.0, 138.0, 134.6, 133.3, 133.2, 128.6, 128.0, 127.8, 127.1, 126.5, 
126.3, 125.8, 111.0, 93.0, 83.4, 77.4, 73.1, 72.9, 62.2, 12.4; HRMS (ESI) calc’d for C21H23N2O6 
[M+H]+ m/z = 399.15506, found 399.15546; calc’d for C21H22N2NaO6 [M+Na]+ m/z = 
421.13701, found 421.13759; [α]D25: ˗20 (10 mg/mL, CH2Cl2). 
 
 
1-((2R,3R,4R,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)-4-(naphthalen-2-
ylmethoxy)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (20). Imidazole 
(720 mg, 10.6 mmol) and TBSCl (1.58 g, 10.5 mmol) were added to a solution of nucleoside 19 
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in anhydrous DMF (12 mL). After stirring for 15 hours, EtOH (10 mL) and 1 M HCl (10 mL) 
were added. The layers were separated and the aqueous layer was extracted with Et2O (3 × 10 
mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated under 
reduced pressure to obtain a yellow oil. TFA (0.86 mL, 11 mmol) and 80 % (w/v) AcOH (20 
mL) were added to a stirred solution of the crude oil in THF (2 mL). After stirring at room 
temperature for 6 h, the reaction was neutralized via addition of a saturated solution of sodium 
bicarbonate. The layers were separated and the aqueous layer was extracted with 
dichloromethane (4 × 5 mL). The combined organic extracts were dried over Na2SO4, filtered, 
and concentrated under reduced pressure. The residue was purified by flash chromatography 
(15 × 3 cm, 1:1 EtOAc/hexanes) to give nucleoside 20 (1.16 g, 52% over two steps), Rf = 0.3 
(1:1 EtOAc/hexanes); 1H NMR (300 MHz, CDCl3) δ 9.20 (s, 1H), 7.90 – 7.72 (m, J = 16.4, 10.4 
Hz, 4H), 7.55 – 7.28 (m, 4H), 5.53 (d, J = 5.6 Hz, 1H), 4.94 (d, J = 11.9 Hz, 1H), 4.82 – 4.61 
(m, 2H), 4.33 – 4.21 (m, 1H), 4.10 – 3.99 (m, J = 11.9, 7.5 Hz, 1H), 3.97 – 3.86 (m, 1H), 3.74 
– 3.60 (m, J = 20.0, 9.4 Hz, 1H), 3.22 (s, 1H), 1.89 (s, 3H), 0.92 (s, 9H), 0.11 (d, J = 17.7 Hz, 
6H); 13C NMR (75 MHz, CDCl3) δ 163.5, 150.5, 139.3, 135.4, 133.4, 133.3, 128.6, 128.1, 128.0, 
126.7, 126.5, 126.3, 125.8, 111.0, 95.0, 84.5, 73.2, 73.1, 62.6, 26.0, 25.9, 18.3, 12.5, -4.5, -4.8; 
HRMS (ESI) calc’d for C27H37N2O6Si [M+H]+ m/z = 513.24154, found 513.24233; calc’d for 
C27H36N2NaO6Si [M+Na]
+ m/z = 535.22348, found 535.2241. 
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1-((2R,3R,4S)-3-((tert-butyldimethylsilyl)oxy)-5,5-bis(hydroxymethyl)-4-(naphthalen-2-
ylmethoxy)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (21). Dess-Martin 
Periodinane (1.2 g, 2.9 mmol) and sodium bicarbonate (1.02 g, 11.9 mmol) were added to a 
stirred solution of nucleoside 20 (1.16 g, 2.26 mmol) in anhydrous dichloromethane (12 mL) at 
room temperature, stirred for 1.5 h. EtOAc (10 mL), treated with a 10 % (w/v) aqueous solution 
of Na2S2O3 and stirred until a clear organic phase was obtained. The layers were separated and 
the aqueous layer was extracted with EtOAc (4 × 8 mL). The combined organic extracts were 
dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved 
in THF (18 mL), and stirred with a 37 % aqueous solution of formaldehyde (2.4 mL, 32 mmol), 
and 1 M NaOH (4.5 mL, 4.5 mmol). After 1 h, the reaction mixture was cooled to 0°C and 
sodium borohydride (440 mg, 11.6 mmol) was added. The cooling bath was removed and 
stirring was continued for 3 h at room temperature. The reaction mixture was neutralized via the 
addition of 1 M HCl, and the resulting solution was extracted with dichloromethane (5 × 10 
mL). The combined organic extracts were dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The residue was purified by flash chromatography (4:6 EtOAc:hexanes) to 
give nucleoside 21 (594 mg, 48% over 2 steps); 1H NMR (400 MHz, CDCl3) δ 9.06 (s, 1H), 
7.90 – 7.79 (m, 3H), 7.76 (s, 1H), 7.53 – 7.41 (m, 3H), 7.19 (s, 1H), 5.53 (d, J = 5.4 Hz, 1H), 
5.07 (d, J = 11.5 Hz, 1H), 4.98 – 4.89 (m, 1H), 4.67 (d, J = 11.5 Hz, 1H), 4.40 (d, J = 5.7 Hz, 
1H), 3.78 (d, J = 12.0 Hz, 1H), 3.73 – 3.54 (m, 3H), 3.29 (s, 1H), 2.76 (s, 1H), 1.91 (s, 3H), 0.91 
(s, 9H), 0.14 (s, 3H), 0.03 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 163.8, 150.6, 139.8, 134.9, 
133.3, 133.2, 128.7, 128.0, 127.9, 126.8, 126.5, 126.4, 125. 6, 111.2, 96.4, 88.9, 79.1, 74.5, 73.7, 
64.7, 64.0, 25.8, 18.05, 12.4, -4.6, -4.8; HRMS (ESI) calc’d for C28H38N2NaO7Si2 [M+Na]+ m/z 
= 565.23405, found 565.23545. 
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1-((2R,3R,4S,5S)-3-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)-4-(naphthalen-2-
ylmethoxy)-5-((trityloxy)methyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-
dione (22). Trityl chloride (594 mg, 1.65 mmol), DMAP (14 mg, 0.12 mmol) and triethylamine 
(0.31 mL, 2.2 mmol) were added to a stirred solution of nucleoside 21 (0.59 g, 1.1 mmol) in 
anhydrous DMF (5.5 mL). After stirring at room temperature for 12 h, EtOAc (5 mL) and 1 M 
HCl (5 mL) were added. The layers were separated and the aqueous layer was extracted with 
Et2O (5 × 5 mL). The combined organic extracts were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash chromatography (15 × 
2 cm, 4:6 EtOAc/hexanes) to give nucleoside 22 as a white foam (464 mg, 70% based on 
recovered starting material (133 mg)); Rf = 0.72 (6:4 EtOAc/hexanes); 
1H NMR (400 MHz, 
CDCl3) δ 8.52 (s, 1H), 7.91 – 7.22 (m, 23H), 5.56 (d, J = 6.1 Hz, 1H), 4.98 (d, J = 11.5 Hz, 1H), 
4.95 – 4.89 (m, 1H), 4.64 (d, J = 11.5 Hz, 1H), 4.22 (d, J = 5.1 Hz, 1H), 4.14 (dd, J = 12.2, 3.5 
Hz, 1H), 3.79 – 3.70 (m, 1H), 3.67 (d, J = 10.4 Hz, 1H), 3.27 (d, J = 10.3 Hz, 1H), 3.17 (dd, J 
= 8.7, 3.5 Hz, 1H), 1.99 (s, 3H), 0.85 (s, 9H), 0.11 (s, 3H), 0.04 (s, 3H);  13C NMR (101 MHz, 
CDCl3) δ 162.9, 149.9, 143.3, 138.7, 134.8, 132.7, 132.5, 128.3, 127.6, 127.5, 127.4, 127.3, 
126.6, 125.9, 125.7, 125.6, 125.2, 110.6, 93.7, 88.0, 86.4, 78.5, 77.0, 73.3, 73.2, 65.0, 64.0, 25.2, 
17.5, 12.0, 5.2, 5.4; HRMS (ESI) calc’d for C47H52N2NaO7Si [M+Na]+  m/z = 807.3436, found 
807.34422. 
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1-((2R,3R,4S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldiphenylsilyl)oxy)me-
thyl)-4-(naphthalen-2-ylmethoxy)-5-((trityloxy)methyl)tetrahydrofuran-2-yl)-5-methyl-
pyrimidine-2,4(1H,3H)-dione (23). tert-Butyldiphenylsilyl chloride (0.2 mL, 0.8 mmol) and 
imidazole (53 mg, 0.77 mmol) were added to a stirred solution of nucleoside 22 (464 mg, 0.591 
mmol) in anhydrous dichloromethane (5 mL). After stirring at room temperature for 18 h, 1 M 
HCl (5 mL) was added to the reaction mixture, the layers were separated and the resulting 
solution was extracted with dichloromethane (3 × 5 mL). The combined organic extracts were 
dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified 
by flash chromatography (16 × 2.5 cm, 1:4 EtOAc/hexanes) to give nucleoside 23 as a white 
foam (485 g, 80%), Rf = 0.44 (1:4 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 9.25 (s, 1H), 
7.97 – 7.17 (m, 32H), 6.31 (d, J = 6.6 Hz, 1H), 5.06 (d, J = 11.7 Hz, 1H), 4.67 (d, J = 11.7 Hz, 
1H), 4.62 – 4.55 (m, 1H), 4.25 (d, J = 5.1 Hz, 1H), 4.13 (d, J = 11.2 Hz, 1H), 3.92 (d, J = 11.3 
Hz, 1H), 3.68 (d, J = 10.3 Hz, 1H), 3.25 (d, J = 10.3 Hz, 1H), 1.73 (s, 3H), 1.15 (s, 9H), 0.94 (s, 
9H), 0.18 (s, 3H), 0.08 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 163.9, 150.7, 143.8, 135.7, 135.5, 
135.4, 135.3, 133.2, 133.0, 132.9, 132.2, 130.2, 130.1, 128.7, 128.2, 128.0, 128.04, 127.8, 127.7, 
126.9, 126.4, 126.1, 125.9, 125.7, 114.3, 111.4, 87.5, 87.0, 86.7, 78.4, 75.8, 74.0, 66.8, 64.1, 
27.2, 25.6, 19.5, 17.9, 12.0, -4.6, -4.8; HRMS (ESI) calc’d for C63H70N2NaO7Si2 [M+Na]+ m/z 
= 1045.46138, found 1045.46023; [α]D25=+15 (10 mg/mL, CH2Cl2).  
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1-((2R,3R,4S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldiphenylsilyl)oxy)me-
thyl)-5-(hydroxymethyl)-4-(naphthalen-2-ylmethoxy)tetrahydrofuran-2-yl)-5-methyl-
pyrimidine-2,4(1H,3H)-dione (24). Trifluoroacetic acid (0.35 mL, 4.6 mmol) was added in 
three portions, with 1 minute difference between them to a stirred solution of nucleoside 23 
(0.46 g, 0.45 mmol) in dry dichloromethane (4.0 mL) at ˗45 °C. After 10 min, the reaction was 
neutralized via addition of a saturated sodium bicarbonate solution. The layers were separated 
and the aqueous layer was extracted dichloromethane (4 × 5 mL).  The combined organic 
extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue 
was purified by flash chromatography (15 × 2.5 cm, 3:7 EtOAc/hexanes) to give nucleoside 24 
as a white foam (343 mg, 97%), Rf = 0.17 (1:4 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 
9.11 (s, 1H), 7.91 – 7.21 (m, 18H), 6.18 (d, J = 6.3 Hz, 1H), 5.13 (d, J = 11.7 Hz, 1H), 4.62 (d, 
J = 11.7 Hz, 1H), 4.59 – 4.51 (m, 1H), 4.30 (d, J = 5.5 Hz, 1H), 3.85 (d, J = 11.3 Hz, 1H), 3.76 
(d, J = 11.3 Hz, 1H), 3.71 (s, 2H), 2.49 (s, 1H), 1.61 (s, 3H), 1.10 (s, 9H), 0.94 (s, 9H), 0.17 (s, 
3H), 0.02 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 163.8, 150.6, 135.9, 135.5, 135.3, 134.8, 
133.3, 133.2, 132.8, 132.0, 130.2, 130.2, 128.8, 128.1, 128.1, 128.1, 127.9, 126.9, 126.5, 126.3, 
125.7, 111.5, 88.4, 87.5, 78.8, 75.8, 74.4, 66.5, 63.7, 27.2, 25.7, 19.5, 18.0, 12.0, -4.5, -4.7; 
HRMS (ESI) calc’d for C44H56N2NaO7Si2 [M+Na]+ m/z = 803.35183, found 803.3521; [α]D25: 
+38 (10 mg/mL, CH2Cl2).  
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1-((2R,3R,4S,5S)-3-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldiphenylsilyl)oxy)me-
thyl)-5-((S)-1-hydroxyethyl)-4-(naphthalen-2-ylmethoxy)tetrahydrofuran-2-yl)-5-methyl-
pyrimidine-2,4(1H,3H)-dione (25). Dess-Martin periodinane (0.34 g, 0.80 mmol) and sodium 
bicarbonate (0.20 g, 2.4 mmol) were added to a stirred solution of nucleoside 24 (0.34 g, 0.44 
mmol) in anhydrous dichloromethane (5 mL). After stirring at room temperature for 1 h, 
dichloromethane (5 mL) and a 10 % (w/v) aqueous solution of Na2S2O3 were added and stirred 
until a clear organic phase was obtained. The layers were separated and the aqueous layer was 
extracted with dichloromethane (4 × 5 mL). The combined organic extracts were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in dry 
toluene (3.0 mL) at 0 °C and stirred with 2 M AlMe3 in hexanes (0.61 mL, 1.2 mmol). After 1 
h, the reaction mixture was diluted with 1 M HCl (5 mL), the layers were separated and the 
aqueous layer was extracted with dichloromethane (4 × 5 mL). The combined organic extracts 
were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was 
purified by flash chromatography (15 × 2.5 cm, 4 % MeOH in dichloromethane) to give 
nucleoside 25 as a white foam (189 mg, 60% over two steps), Rf = 0.54 (2:3 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 8.64 (s, 1H), 7.92 – 7.24 (m, 18H), 6.19 (d, J = 7.2 Hz, 1H), 5.23 
(d, J = 11.4 Hz, 1H), 4.59 (d, J = 11.4 Hz, 1H), 4.56 – 4.50 (m, 1H), 4.32 (d, J = 5.2 Hz, 1H), 
4.26 – 4.17 (m, 1H), 4.01 (d, J = 11.3 Hz, 1H), 3.89 (d, J = 11.3 Hz, 1H), 2.64 (S, 1H), 1.62 (s, 
3H), 1.15 (s, 9H), 1.01 (d, J = 6.7 Hz, 3H), 0.92 (s, 9H), 0.16 (s, 3H), -0.04 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 163.5, 150.6, 135.6, 135.6, 135.4, 134.6, 133.4, 133.3, 132.9, 132.0, 130.4, 
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130.3, 129.2, 128.2, 128.1, 128.0, 127.3, 126.6, 126.5, 125.8, 114.4, 111.7, 88.2, 86.7, 79.2, 
76.4, 74.9, 67.7, 64.3, 27.3, 25.7, 19.6, 17.9, 16.2, 12.0, -4.3, -4.8; HRMS (ESI) calc’d for 
C45H58N2NaO7Si2 [M+Na]
+ m/z = 817.36748, found 817.36887; [α]D25: +14 (10 mg/mL, 
CH2Cl2).  
 
 
(S)-1-((2R,3S,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-2-(((tert-butyldiphenylsilyl)oxy)me-
thyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-(naphthalen-2-ylmethoxy)-
tetrahydrofuran-2-yl)ethyl methanesulfonate (26). Methanesulfonyl chloride (4 µL, 0.05 
nmol) and 4-dimethylaminopyridine (1 mg, 0.02 mmol) were added to a stirred solution of 
nucleoside 25 (21 mg, 0.020 mmol) in anhydrous pyridine (0.3 mL) at 0 °C. The ice bath was 
removed and the reaction mixture was stirred at room temperature for 10 h, and then diluted 
with HCl 1 M (1 mL) and EtOAc (1 mL). The layers were separated and the aqueous layer was 
extracted with EtOAc (4 × 1 mL). The combined organic extracts were dried over Na2SO4, 
filtered, and concentrated under reduced pressure. The residue was purified by flash 
chromatography (10 × 1.5 cm, 3:7 EtOAc/hexanes) to give nucleoside 26 (22 mg, 95%), Rf = 
0.44 (4:6 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 7.91 – 7.78 (m, 4H), 
7.68 – 7.27 (m, 14H), 6.21 (d, J = 7.7 Hz, 1H), 5.18 – 5.06 (m, 2H), 4.63 (d, J = 11.5 Hz, 1H), 
4.55 (dd, J = 7.6, 5.5 Hz, 1H), 4.21 (d, J = 5.3 Hz, 1H), 3.89 (d, J = 11.3 Hz, 1H), 3.74 (d, J = 
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11.3 Hz, 1H), 2.61 (s, 3H), 1.67 – 1.47 (m, 6H), 1.11 (s, 9H), 0.89 (s, 9H), 0.09 (s, 3H), -0.08 
(s, 3H). 
 
 
1-((1S,3R,4R,6R,7S)-1-(((tert-butyldiphenylsilyl)oxy)methyl)-6-methyl-7-(naphthalen-2-
ylmethoxy)-2,5-dioxabicyclo[2.2.1]heptan-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione 
(27). Thirty seven percent (w/v) HCl (0.10 mL, 1.2 mmol) was added to a stirred solution of 
nucleoside 26 (10 mg, 0.011 mmol) in THF (0.07 mL) and MeOH (0.13 mL). After heating at 
reflux for 4 h, the reaction mixture was cooled and neutralized via addition of saturated sodium 
bicarbonate solution. Dichloromethane (2 mL) was added, then the layers were separated and 
the aqueous layer was extracted with dichloromethane (4 mL). The combined organic extracts 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude residue 
Rf = 0.19 (1:1 EtOAc/hexanes), was dissolved in MeOH (1 mL) and mixed with potassium 
carbonate (10 mg, 0.071 mmol). After heating to reflux for 1 h the reaction was diluted with 
dichloromethane, filtrated and concentrated under reduced pressure. The residue was purified 
by flash chromatography (6 × 1 cm, 1:1 EtOAc:hexanes) to give nucleoside 27 (5.3 mg, 70%) 
Rf = 0.84 (6:4 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 7.93 (s, 1H), 7.88 – 7.27 (m, 
18H), 5.63 (s, 1H), 4.84 (s, 1H), 4.74 (d, J = 11.5 Hz, 1H), 4.52 (s, 1H), 4.32 (d, J = 6.5 Hz, 
1H), 4.21 (s, 1H), 3.92 (s, 2H), 1.57 (s, 3H), 1.20 (d, J = 6.4 Hz, 3H), 1.10 (s, 9H). 
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1-((2R,3R,4S,5S)-3-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldiphenylsilyl)oxy)me-
thyl)-5-((R)-1-hydroxyethyl)-4-(naphthalen-2-ylmethoxy)tetrahydrofuran-2-yl)-5-me-
thylpyrimidine-2,4(1H,3H)-dione (28). Dess-Martin Periodinane (92 mg, 0.21 mmol) and 
sodium bicarbonate (0.10 g 1.2 mmol) were added to a stirred solution of nucleoside 25 ( 0.13 
g, 0.17 mmol) in anhydrous dichloromethane (1.0 mL). After stirring at room temperature for 
1.5 h, dichloromethane (1 mL) and a 10 % (w/v) solution of Na2S2O3 were added and stirred 
until a clear organic phase was obtained. The layers were separated and the aqueous layer was 
extracted with dichloromethane (4 × 2 mL). The combined organic extracts were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in dry 
THF (1.0 mL) and stirred with lithium aluminum hydride (24 mg, 0.63 mmol) at ˗78 °C. After 
1 h, the reaction was diluted with ethyl acetate (3 mL) and HCl 1 M (3 mL), then extracted with 
dichloromethane (4 × 4 mL). The organic extractions were combined, dried over Na2SO4 and 
evaporated under reduced pressure. The residue was purified by flash chromatography (15 × 2 
cm, 3:7 EtOAc/hexanes) to give nucleoside 28 as a white foam (97 mg, 73% over two steps), Rf 
= 0.19 (5% acetone in dichlorometane); 1H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 11.1 Hz, 
1H), 7.92 – 7.17 (m, 18H), 6.22 (d, J = 6.6 Hz, 1H), 5.13 (d, J = 11.5 Hz, 1H), 4.65 (d, J = 11.5 
Hz, 1H), 4.60 – 4.47 (m, 1H), 4.43 – 4.30 (m, 1H), 4.18 – 4.04 (m, 1H), 3.79 (d, J = 10.9 Hz, 
1H), 3.59 (d, J = 11.1 Hz, 1H), 3.31 (s, 1H), 1.64 (s, 3H), 1.16 – 0.98 (m, 12H), 0.91 (s, 9H), 
0.12 (s, 3H), -0.02 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 163.7, 150.4, 136.2, 135.6, 135.4, 
134.8, 133.3, 133.2, 132.7, 132.0, 130.3, 130.27, 128.6, 128.2, 128.1, 128.0, 127.9, 126.8, 126.4, 
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126.3, 125.7, 111.5, 89.3, 88.9, 79.6, 75.7, 74.5, 68.6, 65.8, 27.3, 27.2, 25.7, 19.5, 17.9, 16.6, 
12.0, -4.4, -4.7; HRMS (ESI) calc’d for C45H59N2O7Si2 [M+H]+ m/z = 795.38553, found 
795.3851; calc’d for C45H58N2NaO7Si2 [M+Na]+ m/z = 817.36748, found 817.36765; [α]D25: 
+30 (10 mg/mL, CH2Cl2).  
 
 
(R)-1-((2R,3S,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-2-(((tert-butyldiphenylsilyl)oxy)-
methyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-(naphthalen-2-ylmeth-
oxy)tetrahydrofuran-2-yl)ethyl methanesulfonate (29). Methanesulfonyl chloride (15 µL, 
0.64 mmol) and 4-dimethylaminopyridine (3 mg, 0.02 mmol) were added to a stirred solution 
of nucleoside 28 (97 mg, 0.12 mmol) in anhydrous pyridine (1 mL) at 0 °C. The reaction was 
stirred at room temperature for 12 h, and then diluted with HCl 1 M (2 mL) and EtOAc (2 mL). 
The layers were separated and the aqueous layer was extracted with EtOAc (4 × 2 mL). The 
combined organic extracts were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The residue was purified by flash chromatography (2 × 15 cm, 1:4 EtOAc/hexanes) to 
give nucleoside 29 (78 mg, 74%), Rf = 0.89 (1:1 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) 
δ 8.83 (s, 1H), 7.91 – 7.28 (m, 18H), 6.26 (d, J = 7.0 Hz, 1H), 5.20 – 5.08 (m, 2H), 4.69 – 4.60 
(m, 1H), 4.54 (d, J = 11.3 Hz, 1H), 4.16 (d, J = 4.8 Hz, 1H), 3.95 (d, J = 11.5 Hz, 1H), 3.88 (d, 
J = 11.5 Hz, 1H), 2.94 (s, 3H), 1.64 (s, 3H), 1.22 – 1.11 (m, 12H), 0.90 (s, 9H), 0.14 (s, 3H), -
0.02 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 163.5, 150.6, 135.6, 135.5, 135.4, 134.4, 133.2, 
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133.2, 132.3, 131.7, 130.6, 130.5, 128.5, 128.3, 128.1, 127.9, 127.0, 126.5, 126.3, 126.0, 111.9, 
87.9, 87.0, 81.0, 78.7, 75.8, 74.7, 63.9, 38.2, 27.3, 25.7, 19.6, 18.0, 17.9, 12.0, -4.4, -4.7; HRMS 
(ESI) calc’d for C46H61N2O9SSi2 [M+H]+ m/z = 873.36308, found 873.36274; calc’d for 
C46H60N2NaO9SSi2 [M+Na]
+ m/z = 895.34503, found 895.34561; [α]D25: ˗14 (10 mg/mL, 
CH2Cl2). 
 
 
1-((1S,3R,4R,6S,7S)-1-(((tert-butyldiphenylsilyl)oxy)methyl)-6-methyl-7-(naphthalen-2-
ylmethoxy)-2,5-dioxabicyclo[2.2.1]heptan-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione 
(30). 37 % (w/v) HCl (0.5 mL) was added to a stirred solution of nucleoside 29 (50 mg, 0.058 
mmol) in THF (0.35 mL) and MeOH (0.5 mL). After 12 h, the reaction mixture was neutralized 
via addition of saturated sodium bicarbonate solution. Dichloromethane (2 mL) was added, then 
the layers were separated and the aqueous layer was extracted with dichloromethane (4 × 2 mL). 
The combined organic extracts were dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The residue was purified by flash chromatography (2 × 15 cm, 1:1 
EtOAc/hexanes) to give 2’-OH free nucleoside (30 mg, 70%). Rf = 0.25 (1:1 EtOAc/hexanes). 
Potassium carbonate (30 mg, 0.21 mmol) was added to a stirred solution of nucleoside 2’-OH 
free nucleoside (30 mg, 0.04 mmol) in MeOH (1.5 mL). After heating to reflux for 1 h the 
reaction was diluted with dichloromethane, filtrated and concentrated under reduced pressure. 
The residue was purified by flash chromatography (8 × 1 cm, 3:7 EtOAc:hexanes) to give 
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nucleoside 30 (24 mg, 92%); 1H NMR (400 MHz, CDCl3) δ 8.24 (s, 1H), 7.86 – 7.64 (m, 8H), 
7.52 – 7.28 (m, 10H), 5.64 (s, 1H), 4.83 (d, J = 11.4 Hz, 1H), 4.70 – 4.62 (m, 2H), 4.16 – 4.06 
(m, 2H), 4.01 (d, J = 12.6 Hz, 2H), 1.59 (s, 3H), 1.33 – 1.24 (m, 3H), 1.09 (s, 9H); 13C NMR 
(75 MHz, CDCl3) δ 163.5, 149.7, 135.7, 135.5, 134.4, 134.2, 133.2, 133.2, 132.9, 132.5, 130.2, 
130.2, 128.6, 128.1, 128.0, 127.9, 127.8, 127.0, 126.6, 126.4, 125.9, 110.4, 89.6, 87.3, 81.2, 
72.7, 59.3, 27.0, 19.6, 16.5, 12.3; HRMS (ESI) calc’d for C39H43N2O6Si [M+H]+ m/z = 
663.2849, found 663.28852; calc’d for C39H42N2NaO6Si [M+Na]+ m/z = 685.270433, found 
685.27056;  [α]D25: +24 (10 mg/mL, CH2Cl2). 
 
5.2.4 Fourth Generation Synthesis 
 
Nucleoside 2: Camphorsulfonic acid (1.41 g, 6.10 mmol) and cyclohexanone dimethyl acetal 
(18.5 mL, 0.122 mol) were added to a stirred solution of 5-methyluridine (15.7 g, 60.7 mmol) 
in 1,2-dichloroethane (230 mL). After refluxing for 2 h, the mixture was cooled to room 
temperature and diluted with dichloromethane (100 mL) and saturated sodium bicarbonate 
solution (100 mL). The layers were separated and the aqueous layer was extracted with 
dichloromethane (3 × 50 mL). The combined organic extracts were dried over Na2SO4, filtered, 
and concentrated under reduced pressure. The crude foam was dissolved in dichloromethane 
(200 mL) and mixed with Dess-Martin periodinane (31.0 g, 73 mmol) and sodium bicarbonate 
(10 g, 12 mmol). After stirring at room temperature for 3 h, ethyl acetate (100 mL) and a 10 % 
(w/v) solution of Na2S2O3 were added and stirred until a clear organic phase was obtained. The 
layers were separated and the aqueous layer was extracted with EtOAc (4 × 50 mL). The 
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combined organic extracts were concentrated under reduced pressure. The residue was dissolved 
in THF (300 mL), and stirred with a 37 % aqueous solution of formaldehyde (90 mL, 1.2 mol), 
1 M NaOH (117 mL, 117 mmol). After 12 h, the reaction mixture was cooled to 0 °C and sodium 
borohydride (11.5 g, 0.30 mmol) was added slowly. The cooling bath was removed and the 
reaction was allowed to warm to room temperature over a 3 h period. The reaction mixture was 
neutralized via the addition of 1 M HCl, and the resulting solution was extracted with 
dichloromethane (5 × 80 mL). The combined organic extracts were dried over Na2SO4, filtered, 
and concentrated under reduced pressure. The residue was purified by flash chromatography to 
give nucleoside 2 as a white foam (14 g, 62%). 
Nucleoside 10: tert-Butyldimethylsilyl chloride (2.86 mL, 18.9 mmol) and imidazole (1.29 g, 
18.9 mmol) were added to a stirred solution of nucleoside 2 (5.37 g, 14.5 mmol) in anhydrous 
DMF (70 mL). After 4 h at 0 °C, the reaction mixture is warmed to room temperature and mixed 
with imidazole (2.00 g, 2.94 mmol) and tert-butyldiphenylsilyl chloride (7.6 mL, 29 mmol). 
After 18 h, the reaction mixture was diluted with methanol (70 mL), then mixed with 
trifluoroacetic acid (11.2 mL, 65.9 mmol) added in three portions with 30 min of difference 
between each one. After 48 h, the reaction mixture was neutralized via addition of saturated 
sodium bicarbonate solution and water (300 mL). The reaction mixture was extracted with 
Et2O/EtOAc 1:1 (4 × 50 mL), the combined organic extracts were washed with 1 M HCl (100 
mL). The organic extracts were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The residue was purified by flash chromatography (17 × 5 cm, 3:7 EtOAc/hexanes) to 
give nucleoside 10 (3.58 g, 40%). The column was flushed with EtOAc and the extract was 
mixed with all the non-combined fractions. The mixture of silylated products was concentrated 
under reduced pressure, dissolved in THF (100 mL) and mixed with 1 M TBAF in THF (50 mL, 
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50 mmol). After 12 h, water (50 mL) was added and the mixture was extracted with 
dichloromethane (4 × 50 mL). The combined organic extracts were dried over Na2SO4, filtered, 
and concentrated under reduced pressure. The residue was purified by flash chromatography to 
give nucleoside 2 as a white foam (1.81 g, 61% of nucleoside 10 brsm). 
Nucleoside 12: Dess-Martin Periodinane (303 mg, 0.714 mmol) and sodium bicarbonate (200 
mg, 2.38 mmol) were added to a stirred solution of nucleoside 10 (334 mg, 0.551 mmol) in 
anhydrous dichloromethane (3 mL). After 2 h, dichloromethane (10 mL) and a 10 % (w/v) 
solution of Na2S2O3 were added and stirred until a clear organic phase was obtained. The layers 
were separated and the aqueous layer was extracted with dichloromethane (4 × 5 mL). The 
combined organic extracts were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. Methyl lithium (1.6 M in diethyl ether) (3.4 mL, 5.44 mmol) was added dropwise to a 
0 °C solution of copper iodide (526 mg, 2.76 mmol) in MTBE (16 mL). After 30 min, the 
solution of the crude aldehyde in MTBE (10 mL) was cannulised quickly to the cuprate 
suspension. The reaction mixture was allowed to reach room temperature in a period of 3 h, then 
saturated ammonium chloride (50 mL) was added and stirred for 10 min. The organic layer was 
separated and the aqueous layer was extracted with dichloromethane (4 × 30 mL). The combined 
organic extracts were dried over Na2SO4, filtered, and concentrated under reduced pressure. The 
residue was purified by flash chromatography (12 × 3 cm, 4:6 EtOAc/hexanes) to give 
nucleoside 12 (175 mg, 51% over two steps). (38 mg of the undesired (S)-alcohol were isolated.) 
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(R)-1-((3a'S,4'R,6'R,6a'R)-4'-(((tert-butyldiphenylsilyl)oxy)methyl)-6'-(5-methyl-2,4-di-
oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrospiro[cyclohexane-1,2'-furo[3,4-d][1,3]di-
oxol]-4'-yl)ethyl 4-methylbenzenesulfonate (31). p-toluenesulfonic chloride (270 mg, 1.42 
mmol) and 4-dimethylaminopyridine (12 mg, 0.10 mmol) were added to a stirred solution of 
nucleoside 12 (0.29 g, 0.46 mmol) in anhydrous pyridine (2.5 mL). The reaction mixture was 
stirred at 70 °C for 12 h, and then diluted with HCl 1 M (10 mL) and EtOAc (5 mL). The layers 
were separated and the aqueous layer was extracted with EtOAc (5 × 5 mL). The combined 
organic extracts were dried over Na2SO4, filtered, and concentrated under reduced pressure. The 
residue was purified by flash chromatography (12 × 3 cm, 4:6 EtOAc/hexanes) to give 
nucleoside 31 (260 mg, 76%) Rf = 0.35 (4:6 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 
8.80 (s, 1H), 7.72 (d, J = 8.3 Hz, 2H), 7.65 – 7.52 (m, 4H), 7.51 – 7.33 (m, 7H), 7.22 (d, J = 8.1 
Hz, 2H), 7.16 (s, 1H), 5.51 (d, J = 5.5 Hz, 1H), 4.93 – 4.81 (m, 1H), 4.63 (t, J = 5.5 Hz, 1H), 
4.42 (d, J = 5.5 Hz, 1H), 3.91 (s, 2H), 2.35 (s, 3H), 1.81 – 1.19 (m, 16H), 1.07 (s, 9H); 13C NMR 
(101 MHz, CDCl3) δ 163.7, 149.9, 144.7, 135.7, 135.4, 135.3, 134.1, 132.4, 131.9, 130.6, 130.5, 
129.3, 128.3, 128.2, 128.1, 115.1, 110.8, 89.3, 88.7, 84.3, 80.9, 80.4, 64.1, 37.3, 34.9, 27.2, 24.9, 
24.1, 23.7, 21.7, 19.4, 17.7, 12.0; LRMS calc’d for C41H50N2NaO9SSi [M+Na]+ m/z = 797.29, 
found 797.1. 
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(R)-1-((2R,3S,4R,5R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3,4-dihydroxy-5-(5-me-
thyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)ethyl 4-methylbenze-
nesulfonate (32). 37 % (w/v) HCl (0.3 mL) was added to a stirred solution of nucleoside 31 (20 
mg, 0.026 mmol) in THF (0.2 mL) and MeOH (0.15 mL). After heating at 50 °C for 9 h, the 
reaction mixture was cooled and neutralized via addition of saturated sodium bicarbonate. 
Dichloromethane (3 mL) was added, then the layers were separated and the aqueous layer was 
extracted with dichloromethane (4 × 2 mL). The combined organic extracts were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash 
chromatography (10 × 1 cm, 6:4 EtOAc/hexanes) to give nucleoside 32 (17 mg, 94%). Rf = 0.14 
(6:4 EtOAc/hexanes); 1H NMR (300 MHz, CDCl3) δ 9.64 (s, 1H), 7.74 (d, J = 8.3 Hz, 2H), 7.64 
– 7.52 (m, 4H), 7.52 – 7.33 (m, 6H), 7.24 – 7.15 (m, 3H), 5.58 (d, J = 7.2 Hz, 1H), 5.09 (q, J = 
6.5 Hz, 1H), 4.46 – 4.34 (m, 1H), 4.24 (d, J = 5.1 Hz, 1H), 3.84 (s, 2H), 3.50 (bs, 2H), 2.33 (s, 
3H), 1.57 (s, 3H), 1.32 (d, J = 6.6 Hz, 3H), 1.03 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 163.8, 
151.7, 144.4, 135.6, 135.6, 135.4, 134.7, 132.4, 131.8, 130.6, 130.4, 129.3, 128.3, 128.2, 128.1, 
110.98, 90.0, 88.5, 81.2, 76.2, 72.9, 64.0, 27.1, 21.7, 19.4, 17.8, 12.2; HRMS (ESI) calc’d for 
C35H43N2O9SSi [M+H]
+ m/z = 695.2453, found 695.24669; calc’d for C35H42N2NaO9SSi 
[M+Na]+ m/z = 717.22725, found 717.22889. 
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1-((1R,3R,4R,6S,7S)-1-(((tert-butyldiphenylsilyl)oxy)methyl)-7-hydroxy-6-methyl-2,5-di-
oxabicyclo[2.2.1]heptan-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (33). A solution of 
nucleoside 32 (50 mg, 72 µmol) in HMPA (0.5 mL) was heated at 150 °C for 1 h. The mixture 
was allowed to cool to room temperature and diluted with water (3 mL). Extractions with Et2O 
(3 × 1 mL) followed by washing of the combined organic extracts with water (2 × 1 mL). The 
combined organic extracts were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The residue was purified by flash chromatography (1 × 8 cm, 1:1 EtOAc:hexanes) to 
give nucleoside 32 (19 mg, 50%). Rf = 0.12 (1:1 EtOAc:hexanes); 
1H and 13C NMR data match 
with previously reported data22. 
 
(R)-1-((2R,3S,4R,5R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3-hydroxy-5-(5-methyl-
2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-((triethylsilyl)oxy)tetrahydrofuran-2-yl)ethyl 
4-methylbenzenesulfonate (34). Triethylsilyl trifluoromethanesulfonate (40 µL, 0.17 mmol) 
was added dropwise to a stirred solution of 2,6-lutidine (40 µL, 0.34 mmol) and 32 (30 mg, 
0.040 mmol) in dichloromethane (0.5 mL) at 0 °C. After stirring for 0.5 h, the reaction mixture 
was diluted with water (1 mL) and stirred for 10 min. Dichloromethane (2 mL) was added, then 
the layers were separated and the aqueous layer was extracted with dichloromethane (4 × 2 mL). 
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The combined organic extracts were dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The residue was purified by flash chromatography (7 × 1 cm, 3:7 
EtOAc/hexanes) to give nucleoside 34 (32 mg, 92%). Rf = 0.15 (3:7 EtOAc/hexanes); 
1H NMR 
(400 MHz, CDCl3) δ 8.42 (s, 1H), 7.70 (d, J = 8.2 Hz, 2H), 7.63 – 7.52 (m, 4H), 7.52 – 7.33 (m, 
6H), 7.24 – 7.11 (m, 3H), 5.65 (d, J = 7.7 Hz, 1H), 4.95 (q, J = 6.5 Hz, 1H), 4.35 – 4.25 (m, 
1H), 4.06 (d, J = 5.1 Hz, 1H), 3.90 (dd, 2H), 2.96 (s, 1H), 2.34 (s, 3H), 1.45 (s, 3H), 1.35 (d, J 
= 6.5 Hz, 3H), 1.11 (s, 9H), 0.85 (t, J = 7.9 Hz, 9H), 0.56 – 0.38 (m, 6H); HRMS (ESI) calc’d 
for C41H57N2O9SSi2 [M+H]
+ m/z = 809.33178, found 809.32779; calc’d for C41H60N3O9SSi2 
[M+NH4]
+ m/z = 826.35833, found 826.36833. 
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